Dominic D'Agostino, Ph.D. on Modified Atkins Diet, Ketosis, Supplemental Ketones and More
Posted on April 10th 2016 (about 3 years)
This podcast is with Dr. Dominic D'Agostino, an assistant professor at the University of South Florida in Tampa and all around expert on ketosis.
In this episode we discuss...
- Dom's efforts at teasing out the differences between induced nutritional ketosis (through a low carbohydrate, high fat diet) and ketosis from the dietary introduction of exogenous ketones, like beta-hydroxybutyrate, especially in the context of therapeutic and performance enhancing effects.
- His work on formulating ketone esters.
- The differences in tolerability between MCT (medium chain triglycerides) powders versus liquids, as well as the amount of supplemental MCT a person would need to consume to achieve mild ketosis without carbohydrate restriction.
- The differences between different types of ketogenic diets.
- The modified atkins diet which has been demonstrated to have similar efficacy to the classical ketogenic diet in the treatment of drug-resistant epilepsy and how it may be a slightly more practical option for achieving therapeutic nutritional ketosis.
- The importance of making the correct carbohydrate choices, even and maybe especially in the context of a ketogenic diet, with a diverse variety of raw vegetables being the most favorable.
- What keto-adaptation is and what it means, at a physiological level, to be keto-adapted and how this is distinguished from short periods of ketosis we experience in our day-to-day lives.
- Some of Dom's ideas around cycling various dietary strategies as a way of promoting metabolic flexibility.
- How ketones, when used as a source of energy, may result in a net reduction in the number of damaging reactive byproducts known as reactive oxygen species than what may be produced by other forms of energy metabolism while also producing more ATP from, proportionately, the same amount of oxygen.
... and much more!"The ketones themselves are anti-catabolic for protein sparing. So if you're in a state of ketosis, you're protecting gluconeogenic amino acids and skeletal muscle from being degraded." - @DominicDAgosti2 Click To Tweet
Learn more about Dr. Dominic D'Agostino
- Craig Thompson
- Eric Verdin - episode with Dr. Verdin
- Eric Kossoff
- George Brooks - episode with Dr. Brooks
- Jeff Volek
- Joe LaManna
- John Freeman
- Nate Ward
- Stephen Phinney
- Stephen Cunnane
- Tom Seyfried
- Ralph DeBerardinis
- Richard Veech
Rhonda: Hello, everyone, I'm sitting here with Dr. Dominic D'Agostino in Tampa, Florida. Dominic is an assistant professor at the University of South Florida where his primary research focus is on metabolic therapies, particularly nutritional ketosis, ketone supplementation, and how they affect a wide variety of pathological conditions ranging from neurological disorders like ALS to epilepsy to muscle wasting and cancer. So very, very interesting stuff that Dominic's doing here in Florida. He showed me some of his really cool equipment, which is super-exciting and very interesting. Some things I hadn't seen before. So welcome, Dominic.
Dom: Thanks for having me.
Rhonda: Yeah, thanks for inviting us to your lab.
Dom: Great to have you here in my lab, yeah.
Rhonda: So tell us a little bit about your...some of your more recent interests and research where you're, sort of, been, what have you been looking at.
Dom: Okay, so more recently, I'd say within the last three to five years, and it took a while to develop them, but as you know we're working on ketone supplementation. And the idea is to, kind of, mimic the therapeutic effects and performance-enhancing effects of the ketogenic diet. So nutritional ketosis achieved through a dietary means with a low-carbohydrate, high-fat diet has therapeutic effects for a broad range of neurological disorders, in particular, seizures. And you can make the argument that pretty much every neurological disorder is some way linked to a metabolic dysregulation. And we're interested in understanding how nutritional ketosis may help to preserve and, sort of, stabilize brain energy metabolism to metabolically manage these seizure disorders.
So in the process of understanding and studying the ketogenic diet, we are developing a broad range of ketone supplements which can include ketone esters and ketone mineral salts, which where we combine a ketone body, beta-hydroxybutyrate, to an essential electrolyte and create a wide variety of salts. And we're working...a lot of the work now is focused on formulating these to make them tolerable, to make them palatable, and to understand their therapeutic potency for different types of disorders.
Rhonda: Yeah, so you mentioned that at the root, or at the heart of a lot of these neurological disorders is a metabolic dysfunction and how, first of all, when we talk about nutritional ketosis, to me, it's so, it's such a broad way of describing.
Dom: Very broad.
Rhonda: What is nutritional ketosis? Like, and how do you achieve it?
Dom: So nutritional ketosis could be, it's defined...they, kind of, have the same definition in my mind. It's achieving and sustaining a level of blood ketones. And I think when people say they've done the ketogenic diet, they did that it didn't work for them or it did work for them, I would ask the question, "Well, did you measure blood ketones? Did you confirm, in fact, that you were able to achieve a state of ketosis?" Defined as an elevation of blood ketones above 0.5 millimolar at the very least. Ideally, you want to stay between one and three millimolar of ketones. And when you've achieved that state...
Rhonda: You're talking about blood ketones?
Dom: I'm talking about blood ketones, yeah, which is, kind of, the gold standard. And this can be measured. There's a number of different devices out there that measure blood ketones. And when that...the state of nutritional ketosis is achieved, you're also, not only not only that biomarker is, kind of, there and we have technologies to measure it, but it would also be important to measure your blood glucose and maybe insulin levels, too. The suppression of the hormone insulin drives hepatic ketogenesis and drives the body's ability to make ketones. And that has therapeutic implications for type 2 diabetes, obviously.
So my definition of nutritional ketosis would be an elevation of blood ketones and the, kind of, the difficulty in prescribing that or telling someone to do it is that the way to implement that is, kind of, similar with everyone, but everyone responds differently depending on where you're coming from. So if you have an obese subject that's type 2 diabetic, it's going to be different than an athlete. And women, there's some differences between women and men, I think. So defining nutritional ketosis is relatively easy with an elevation of blood ketones, but implementing it and being able to, for the individual to commit to it and have that, kind of, ability to control their diet, which is very linked to lifestyle, has been, sort of, a difficult thing to do. And that's where ketone supplementation, kind of, comes in and can allow someone to rapidly achieve nutritional ketosis and sustain it and perhaps get many of the therapeutic benefits that we're just finding out now. We know that ketones are more than just a metabolite. They are more than just an energy metabolite that the brain can use, but they are metabolites, especially beta-hydroxybutyrate, are very powerful signaling molecules. And we're just beginning to understand, sort of, the therapeutic effects of these metabolites as signaling molecules and that's a big thrust of our lab right now.
Rhonda: Oh, you're interested at looking at this and the effects...
Rhonda: Interesting, I'm familiar with some of Eric Verdin's work at Gladstone and how he's... The science...
Dom: He's a pioneer in...
Rhonda: I'm very interested in beta-hydroxybutyrate as not only as a source of energy for mitochondria. So being able to be converted into a thermodynamically favorable source of energy, but also the fact that it's able to change cell signaling in the brain and it's able to turn on genes that are involved in dealing with stress better, some of these genes are involved in longevity, FOXO3 for one.
Rhonda: So it's all very interesting. But something that I...like, in my mind that I'm not exactly certain about is that nutritional ketosis. So eating a high-fat diet and, of course, there's, okay, what types of fat are you eating? Are you eating more polyunsaturated, you're eating more saturated? You know, how much protein are you eating? What types of carbohydrates? Are you getting fiber? I mean, there's so many diets, very complicated. But there is no doubt that there are interesting therapeutic effects from nutritional ketosis. I am interested in the the actual end product, which is ketone bodies and these signaling molecules like beta-hydroxybutyrate being able to get those maybe even without having to eat a high-fat diet, you can get them from fasting, from intense exercise, right? Also, you can achieve...
Dom: Post-exercise ketosis.
Rhonda: Post exercise.
Rhonda: So, I guess, the, kind of, the question I had for you with nutritional ketosis besides having to define it was, what do people eat to obtain that? How do you get blood ketone levels between one and three millimolar? Like, what do you have to eat? What do you not have to eat?
Dom: Okay, that is a good question and it varies depending on who you talk to and what's optimal. I think a good way to approach it would to be describe what has been used classically and how the diet has evolved over the last two to three decades, I think, with some of the work with Eric Kossoff at Johns Hopkins has, kind of, advanced the idea of using a modified Atkins diet or modified ketogenic diet. And I can, kind of, talk a little bit about strategies that I use, I think, and others that I know use to achieve that state and sustain it for optimal performance in health, I think.
So in taking a step back, the classical ketogenic diet would be like a 4:1 or 3:1 diet, and that's, kind of, the ratios of the macronutrients. Four being fat and one being a combination of carbohydrates and protein together. So a pretty protein-restricted diet. And the ketogenic diet is not a high-protein diet. It's actually moderate to low protein diet. And most people don't understand that, they think, especially in the fitness community, if they go on a ketogenic diet...if they say they've been on a ketogenic diet, what they will describe to me would be a very low-carbohydrate, high-protein, moderate-fat diet, but the ketogenic diet as it is used classically for drug-resistant epilepsy, the original was, like, 90% fat, like 85% to 90% fat and maybe about 10% protein, typically, and 8% to 10% protein, and a very minimal amount of carbohydrates, and it was heavily based upon the used of dairy fat.
So dairy was the primary, kind of, vehicle, yeah, to get calories into you. And we know that the use of dairy especially in some people, dairy protein in particular, but even sometimes dairy fat, too, can have negative consequences for some people. So there's a wide variety of, kind of, ketogenic diets out there and they, the ketogenic diet has been defined by this ratio of macronutrients. But what we're learning now is that it's more than just macronutrients to optimize the diet, especially for individuals. The sources of the macronutrients, the fatty acid profile, the type of protein, it allows for some amount of carbohydrates, and the types and quality of the carbohydrates as it relates to gut health and gut microbiome, I think, is really important. I think it's really important to optimize the diversity of carbohydrate sources in the form of raw vegetables, and I think that it can optimize the diversity of the gut microbiome, too. I think those two are linked, the diversity of the foods in your diet and the diversity of your gut microbiome. I've seen that just through feedback. It's not really studied, but it's something everyone knows and it should be studied.
So the classical ketogenic diet is very strict to follow. There's a few studies showing that it can influence a lipid profile in a negative way, meaning a high elevation of LDL. And in kids, I think, that follow the diet, they had a high level of triglyceride. There was one study that's often referenced in regard to the ketogenic diet being atherogenic the triglycerides are really high in some of the kids.
Rhonda: It's probably a very complex gene-nutrient interaction, as well.
Dom: Absolutely, yeah.
Rhonda: There's some, I'm not sure if you're familiar with any of this work. It's something I'm getting into recently is this nutrigenomic field and particularly, there is PPAR-gamma and PPAR-alpha, which is important for ketosis and polymorphisms that are associated with not being able to respond well, so it's very likely that some of these people that don't respond well or may have that polymorphism.
Dom: Yeah, undoubtedly, because there are some people that really have a negative effect, but I would it's, kind of, few and far between...maybe as high as 20% in some circles, but generally speaking, if you have a dietitian that's pretty savvy and has worked with enough people, I really emphasize experience because there's no substitute for experience. So you could know as much...yeah, you could know the biochemistry behind nutritional ketosis, all the pathways, whatever, but working with a dietitian, I always stress that in people that want to try the ketogenic diet to start off with a good dietitian. They can tailor and tweak the diet for your specific needs and I find that, for me, personally, a diet that's low in dairy is really essential because I just don't do good with dairy, and nuts have been a staple for some people for the ketogenic diet and I have, like, a mild nut allergy. So that's another food that I've, kind of, had to eliminate. But despite that, I have been following what I call a modified ketogenic diet and I think it's pretty similar to the modified Atkins diet that Eric Kossoff has been using at Johns Hopkins. He's at Johns Hopkins, mainly a neurologist, but has a team of dietitians working with him and has done an incredible job advancing, sort of, the use of the ketogenic diet. You know, he follows in the steps of John Freeman, who was really a pioneer in getting the neurology world to recognize a ketogenic diet as a viable metabolic therapy for drug-resistant epilepsy. And he did a lot of work with The Charlie Foundation and worked with them to help promote awareness of the diet, education of the diet.
So some work that Eric Kossoff has been doing over the years and publishing on is showing that the modified Atkins diet has much of the therapeutic potency of the strict classical 4:1 ketogenic diet. So instead of 90% fat, the modified Atkins diet is roughly 65% to maybe 70% fat which is, kind of, what I follow now, and about 20% to 30% protein, with the balance being still very low on carbohydrates, like no more than 5% or 10% carbohydrates. But it's more liberal in the use of protein. And it's also, advocates the use of medium-chain fatty acids, can be incorporated into that. So by following a diet that's more liberal with the protein and less not restrictive, and less in of a need of a such a high-fat content, I've been able to maintain a moderate state of ketosis as do many of the therapies or many of the patients that are benefiting from this therapy for a wide range of disorders.
So I think that makes the diet more accessible to people, and I think the biggest hurdle now is just compliance. So people know the benefits of the diet, some of them are a little concerned with the side effects of the diet as far as lipid profiles being altered.
Rhonda: What about gut?
Dom: The gut, yeah.
Rhonda: Have you been looking...how long have you been doing this modified ketogenic diet?
Dom: It, sort of, evolved from 2008 to '09, I started experimenting with it because that's when I got interested in using...
Rhonda: And you've continued on ever since then?
Dom: Yeah, I've never really gotten out of ketosis.
Rhonda: It's quite a long time. That's quite a long time.
Dom: Yeah. If I did, I may have reverted back to, like, a low-carb Paleo which is maybe up to 40% to 50% fat or protein on some days. So I've been a little more liberal on the protein at times, but yeah, I've been following it for a long time. And I do blood work really consistent.
Rhonda: Well, the reason I ask is because, it's the one, like I mentioned, I'm very interested in nutritional ketosis, which is why I'm excited to talk to you because you know so much more about it. And I'm trying to, like, get to the bot-,...there's this conflict in my head with eating a lot of fat and its effects on the gut because I know a lot of my gut researchers, a lot of my friends are, kind of, looking at gut health and one of the main things that you do induce endotoxin, which is released from bacterial cell membranes. I remember it's one of main things needed to induce gut permeability is if you have a high-fat diet. You feed mice, you feed...this is all done in animals, of course, which is... There's lots of problems with that, but...
Dom: What's the typical fat source for that? Is it lard or is it...?
Rhonda: A variety of different fat sources. There's lard, there's corn oil. I mean, so there's there's a variety of different fat sources, but fat itself in order to be digested, you have make these bile acids like deoxycholic acid, which which causes endotoxin release. It also acts as a surfactant. I mean, it's like a detergent. So, I'm not convinced that it's not not healthy, but I'm not...I'm, sort of, trying to get to the...there's a disconnect in the literature because there's so much information out there showing the benefits of a ketogenic diet, nutritional ketosis.
Dom: Let me ask this question real quick. So when endotoxin is released from these bile acids, so there would be a predictable, a characteristic cytokine profile that would reflect that, right?
Rhonda: Yes, so there's a cytokine profile and you also measure endotoxin in the blood, which is a very tricky thing to do because there's a lot of false positives and I know someone who's trying to develop an assay to make it actual-, because he's very OCD about it. It's not out there for clinical use yet because of that reason, and even doing it in animal studies, there's a lot of researchers that don't really do it right, measuring endotoxin.
Dom: Is there any benefit to endotoxin? So when I go exercise right, and you measure my blood and we look at reactive oxygen species or inflammatory mediators, you could look at the blood and say, "Don't do that, this is not a good thing to do." Whereas if you have periodic spikes maybe and endotoxin, is it stimulating a hormetic effect where it's enhancing my resilience or resistance to toxins, do we know that?
Rhonda: So endotoxin, I would say based on everything that I have known and researched and from my interactions with people that have been doing this research. It's not like reactive oxygen species where there's it's a potent signaling molecule that has this hormetic effect, increases mitochondria biogenesis, it increases all these genes involved in dealing with stress there's lot of benefits. You know, endotoxin release from the gut, one, it causes more VLDL production because VLDL sucks soaks it up. So that's part of the reason why inflammation is also correlated with an increase in LDL number. It also binds to ApoB, it binds to the part, it binds to where the LDL receptors bind so that LDL can't be recycled as well. So it, kind of, prevents. There's a lot of bad things about endotoxin being released. Now I don't know, maybe there is some, sort of, slight benefit from endotoxin being released. You know, I don't want to get too into the endotoxin world. I'm just saying there is, in my...I'm trying to, like, understand in my mind how....
Dom: So you might be a little biased because some of the high-fat diet work has endotoxin. I'm a little bit, I need to get educated, I mean, I understand endotoxin from, kind of, like a basic science point of view.
Rhonda: Right, like, "sepsis, bad."
Dom: Yeah, from "sepsis, bad," but I do know when your body is challenged, even things like radiation. I mean, there are some things...you know, I don't know of any case where an auto antibody is a good thing, but I know most of the things that are bad out there do have some benefits, it's the level it's the level.
Rhonda: Absolutely, dose is very important.
Dom: And the phenotype's ability to adapt to that chemical, that stimulus is really important. Like, old people don't adapt to older phenotypes don't adapt to an oxidative stress stimulus as robust. So I would be interested, and there's ways to simulate endotoxin, right? Experimental models and that's something we can do, challenge, perhaps run an experiment where we have animals on different diets where we can challenge them and look at inflammatory cytokines. We're doing a lot of that work now.
Rhonda: And gut health in general, gut permeability. I would love to see some ketogenic research go in that direction because there's so many unanswered questions in my mind. And there's a lot of bad data out there, like so from the high-fat diet and the effects on the gut because when you look at controlled diets and the high-fat diet, well, the controlled diets have, like, 50% more fiber, and it's like, "Well, that's not really the same thing if you're just changing fat." So there's, you have sift through all sorts of crap, and it's, like, there's lots of data you just have to throw out, but still at the end of the day, I'm uncertain and I'm weary about me, eating a high-fat diet. Not not mention the fact that I have certain gene polymorphisms that may not be as compatible, but because of that, because of gut health, that's my major, the limiting factor for me is gut health and I like to see more research on ketogenic diets and gut health, like, that's something that I think is important.
Dom: How to optimize it.
Rhonda: Yeah, or just what the effects are, like maybe they're for one, we're starving out probably a lot of the pathogenic sugar-eating bacteria. So there's probably some good things going on. And then there's, well, what effect does medium-chain triglycerides has? Is it the same as long-chain fats? Maybe not. So maybe...so there is different types of fat there's studies that had been coming out very recently showing the effects of polyunsaturated fat on the gut biome, and how it has a positive effect. So maybe if you eat certain types of fat, more of these types of fat versus the others. There's lot of things out there to be explored.
Dom: Undoubtedly shifts it, yeah. It shifts it. I mean, your gut microbiome has an appetite for whatever you're feeding it and that probably influences profoundly your own appetite. So I think if you have sugar-eating gut microbes, you're probably going to be craving sugar if you go a few hours without having sugar. And I think I would be very interested in not only, like, shifting someone from a high-carb diet to two or three different types of ketogenic diets, I think, would be important with specific fatty acid compositions and fiber compositions. And I think it's the diversity of the fiber that's incorporated.
Rhonda: Diversity, yes, it is very important. There have been there's lots of different types of bacteria and they're eating different precursors to generate a lot of these other signaling molecules, short chain fatty acids and things like that that are regulating your immune system, that are regulating literally hematopoiesis, Tregs, natural killer cells lots of...and this is a whole blooming field of research. That's also another reason I've been a little hesitant to experiment with this because I'm so, fiber is so important for me, fiber from vegetables. You know, I'm not adverse to fiber from fruits, so fiber from fruits, legumes, beans, like, I like to get a lot of fiber in my diet, and so I don't know if that, is that compatible with it?
Dom: I get more fiber on a ketogenic diet. You know, and we're talking about a well-formulated ketogenic diet, as Jeff Volek likes to... And because that is really important because you talk to people that you eat ketogenic diets and it's all over the board. But I think a well-formulated ketogenic diet would have an abundance of fiber sources, everything from green vegetables, of course, but would include a salad, and I think it's really important from a gut microbiome perspective to get in raw vegetables, I think, from what I've known and a half-dozen individuals that I talk to that are, kind of experts in this field. They think that that has a pretty profound effect, and I have always done that and I would say my gut health has not... It may be due to what I eliminated in my diet. I grew up in an Italian family eating a lot of pasta, bread, so they were the staple foods, and I gravitated toward a Paleo diet mid-90s, early 2000s and then the ketogenic diet, and I have never had better gut health than when on a ketogenic diet, but my diet is, like I said, more of a modified Atkins and has a pretty liberal amount of vegetables in it. And I think the benefit to including the vegetables, they're just carriers for the fat and they also slow protein digestion, which helps minimize the insulin spike that you can get from protein and helps keep me in ketosis.
But, I mean, getting back to your question about the ketogenic diet or high-fat diet influencing endotoxin or factors, I would think that would show up in the literature that if some, and maybe it does, but it usually, a high-fat diet is in the context of a high-carbohydrate diet, too. So that's what we don't know when we talk about LDL particles being elevated, like, even skyrocketed, LDL, little peak. That is only understood in the context of a high-fat diet, which also includes also sugar like a western diet. So we don't yet understand lipidomics and the shifts in lipid profile of the ketogenic diet, LDL(p), specifically, we don't understand it in the context of ketoadaptation.
Rhonda: Okay, what's that?
Dom: Ketoadaptation, I would, it's, kind of, a term that Jeff Volek and Stephen Phinney coined, but I think it's very descriptive in my mind as a physiological process when your body has adapted to using fatty acids and ketones for fuel where you've biochemically and physiologically shifted your metabolism from burning glucose as the primary fuel to burning glucose and also equal or maybe more, in some cases, ketone bodies primarily from your central nervous system. So when that happens, that's acutely, you get an elevation of blood ketones and over time, what you do is get an upregulation of the transport mechanism so your ability to make ketones, utilize ketones, and metabolize ketones in the cell is dramatically increased as is the oxidative capacity of your cells.
Rhonda: After you start making more ketones.
Dom: After, yeah. It's, sort of, driven by being in a state of ketosis enhances fat oxidation over time. So when we say ketoadaptation, we should probably say keto and fat adaptation. So there's studies out there that show our metabolic physiology changes pretty profoundly from eating this. We basically, we burn what we eat, right? So with a high-carbohydrate diet, we are pretty much burning that as fuel and our bodies can adapt remarkably well to burning a macronutrient profile that's reflective of the ketogenic diet. And when we do that, a lot of really remarkable, beneficial metabolic processes happen including mitochondrial biogenesis, reduction of ROS, reduction of inflammation, a reduction of specific inflammatory cytokines that may be associated with with age-related chronic diseases are reduced.
Rhonda: And so reduction of ROS, because I would, no, I guess some of Richard Veech's, have put some ideas out there about the...
Dom: Ketones, direct effect, yeah, on that, too.
Rhonda: Yeah, it's so funny because in my mind I always think about like, well, if you're inducing your mitochondria to work more, you're going to make more reactive oxygen species, right, and that's, sort of, what I think would be a driver of killing abnormal cells, cancer cells that are primed to die. They're expressing way more pro-apoptotic proteins they've countered it with anti-apoptotics. All they need is a little push, a little reactive oxygen species pushed to death.
Dom: And that's increased initially.
Rhonda: It is.
Dom: So yeah, it actually activates like a Nrf2. So when someone gets on a ketogenic diet, it's a stress to the body and you...
Rhonda: Yeah, so you are...you aren't making more, because if you are causing your mitochondria to only work, right, that's the only way you can make energy, then you'd think that you have to be making reactive oxygen species. At least if you're looking in the context of a cancer cell, which just would be glycolytic and not using the mitochondria at all, right? Then definitely there would be a much more, an increase in ROS. So ketone, so you're saying that it can suppress ROS. Is that through some of what Richard Veech has put out there in the semi-ubiquinone, how it's like...
Dom: Oxidize Q, makes it less available.
Rhonda: Yeah, right, because that's the most...
Dom: If Q is oxidized, yeah, so.
Rhonda: So Q being ubiquinone.
Dom: Yeah, ubiquinone. If ubiquinone is oxidized, which is achieved with our beta-hydroxybutyrate metabolism, if that's oxidized, then you have less availability for that electron to react with molecular oxygen in the metabolic pathway. So you would produce less superoxide anion, which is your precursor to more reactive oxygen species. And that's been shown elegantly in a number of models including the cardiac model, which he did, the Langenhorn [SP] model, the perfused heart preparation showing that you get a greater hydrolic efficiency of the heart in the presence of ketones. You know, with a given amount of oxygen, you can generate proportionally more ATP, energy currency.
Rhonda: Is there another way that ketones also suppress ROS? Or is that through the hormetic effect of activating mitochondria, then increasing Nrf2 and things like that?
Dom: Yeah, that would be a secondary effect. I would say from a acute point of view, as simply as a metabolic fuel through the mitochondrial efficiency is greater. So you have a greater mitochondrial membrane potential, a greater driving force for ATP synthase to make ATP. So it energizes the mitochondria in a way that would be expected from a metabolic fuel that's, sort of, superior from a bioenergetic point of view. So you have a greater capacity to generate ATP for a given amount of oxygen that's available. So with that occurring, the metabolic efficiency of the cell would be, sort of, preserved, you're using less oxygen to make the same amount of ATP, less reactive oxygen species. And, of course, if you're shifting away from glycolysis and shifting towards oxidative phosphorylation...
Rhonda: So in the context of a cancer cell.
Dom: In the context of, yeah, any kind of cell, like our tissue, really, skeletal muscle or cancer cell, yeah, you are forcing the body in a way and to stress, initially, to upregulate mitochondrial machinery, really, and more mitochondria will start budding off and creating mitochondrial biogenesis.
Rhonda: So it increases mitochondrial biogenesis.
Dom: Yeah, the number of mitochondria. Then, the proteins that are associated with the electron transport chain, those proteins are upregulated.
Rhonda: That's very interesting. It acts very similar to lactate. I don't know if you're familiar with any of, like, the brain work, and George Brooks, and lactate.
Dom: Yeah. I...very interested in lactate as a graduate student.
Rhonda: Because it does the same thing. Goes to the same transporter, right?
Dom: Yeah, at MCT. I studied lactate as, sort of, an undergrad and graduate student, like, I am studying ketones now as an alternative fuel.
Rhonda: Oh, really? We're you looking at it in the brain?
Dom: Yeah, during hypoxia. So I studied the neural control of autonomic regulation, so brain hypoxia and what our brains do under hypoxia. And lactate is a big player in preserving brain function, viability, health, and I studied lactate as an alternative energy source under hypoxia. And now, I think of ketones as, like, the alternative energy source when your brain is under normal physiology. And I think there are some uses for lactate, too, as a fuel. I think when we exercise we're creating lactate and we feel good, it's not really talked about. It's something that I want to study and maybe talk about a little bit more is that the lactate...you're also sending, not only are you sending ketones to your brain, but you're sending lactate to your brain, and I think that's maybe not talked about that much, but there's a potential out there for lactate supplements.
Rhonda: George Brooks in UC Berkeley, he's...I don't know if you're familiar with any of his work.
Dom: A little bit, yeah, peripherally.
Rhonda: He pioneered the whole lactate shuttle theory, but he's been looking at the effects of lactate generated during exercise, for example, when you're forcing your muscle cells to work harder and you're making more lactate, it gets over, it crosses over the blood-brain barrier gets into neurons. So neurons themselves actually use lactate generated from astrocytes. So they are using, I mean, neurons actually using lactate. It's also a thermodynamically and energetically favorable source of energy much like ketones. And so neurons like doing that because, one, it's easier, and two, because glucose can then be freed up to be shunted into the pentose phosphate pathway, which can be used to generate NADPH, which is important for glutathione recycling.
Dom: Antioxidant capacity, yeah.
Rhonda: Right, which makes sense why... Probably, I think there's a lot of parallels between ketone bodies and ketone supplements and how they're not only being used as a preferential source of energy in the brain. Do you know anything about this, about, like, how frees up glucose then to be used for other...
Dom: Glucose sparing.
Rhonda: ...metabolic pathways? Yeah, glucose sparing.
Dom: Yeah, it's thought that some of the work by Stephen Cunnane, I think, is shedding light on this, too.
Rhonda: Where is he at?
Dom: He's in Canada. I forget the institute that he's at. Joe LaManna has done some similar work and he's at Case Western and looked at the, kind of, the interaction of what does the brain prefer...what's the preferred fuel source for the brain. I get this question a lot. I think it depends on, you know...I don't know if it's right to say that the brain always prefers ketones.
Rhonda: The brain cell we're talking about, for one. The neuron, astrocytes.
Dom: Neurons and astrocytes. But, yeah, I guess, I mean, maybe we're definitely biased towards understanding neurons relative to astrocytes.
Rhonda: I think most people that ask me that question are....
Dom: Astrocytes are fascinating. I think we need to study that more. But I think in the context of, like, aging and a context of traumatic brain injury or pathology, I think the brain will really prefer to use ketones because...or in the context of some kind of stress hypoglycemia or something like that, I think the brain will also prefer to use ketones.
Rhonda: Yeah, so why do you think that is?
Dom: Well, I think...
Rhonda: I might have my own reasons why.
Dom: There's a whole host of reasons or things that can cause impaired brain energy, brain glucose metabolism and that could be internalization of the GLUT3 transporter, which occurs...it's kind of linked to Alzheimer's pathology.
Dom: GLUT3, yeah. And there's a couple of key enzymes that are either deficient or not active like they should be, pyruvate dehydrogenase complex is deficient.
Rhonda: So wait, are these in...are the GLUT3 changes in astrocytes or in neurons?
Dom: Primarily in neurons.
Rhonda: Neurons, okay.
Dom: So the glucose transporter in neurons.
Rhonda: So if neurons are using lactate primarily...the astrocytes are actually what's...
Dom: Shuttling a lot.
Rhonda: The astrocytes are using glucose and that's why the brain needs glucose and they're producing the lactate. The neurons are using the lactate because it's getting shunted and converted into pyruvate.
Dom: And the contribution of that is not completely known, but it's pretty significant contribution during hypoxia, I would think.
Rhonda: There's been studies out there showing that not just during hypoxia, but actually just under normal physiology that...
Dom: It's a key player.
Rhonda: It is, yeah, the neurons are getting lactate continually from astrocytes which are generating it, but that the astrocytes become aberrant during...for whatever reason, it's not known, Alzheimer's leaves traumatic brain injury, so they can't make that lactate and neurons have to start using the glucose, which then is, but I mean, that's just one.
Dom: Yeah, I've heard about that, I haven't looked into that. Yeah, so there's some key enzymes then that people look at not only just the lactate levels...
Rhonda: I think that...I have no idea what they're looking at, but for the pyruvate dehydrogenase complex, you're saying that's also aberrant in some of these disease states because then, you wouldn't be able to use the lactate because you couldn't convert it into pyruvate. So anyways, it's all kind of, I totally interrupted you, though, but you were talking about... What were you talking about, the aberrant enzymes, like GLUT3 and pyruvate dehydrogenase, and how these are aberrant in different neurological disorders.
Dom: Yeah. So I think, I think, well, maybe the question we're trying to get at is the contribution of ketones as a brain energy source and especially in, sort of, in academia and circles where I teach, it's not even, still not really known, it's not really accepted or understood that much. But I think the capacity, the metabolic flexibility of the brain to be able to use ketones, we can exploit that and we do that with nutritional ketosis, and it's altering brain energy metabolism and the neuropharmacology of the brain in ways we don't completely understand now, meaning the neurotransmitters in the brain. So I could draw off GABA. So you have more GABA, the GABA-to-glutamate ratio is shifted in favor of higher GABA. So there's a higher GABA-to-glutamate ratio when one is on the ketogenic diet.
Rhonda: In people that are not having...in normal people, as well? Just, like, in general?
Dom: It's thought that, and there's different reasons for that. There's glutamic acid decarboxylase is an enzyme.
Rhonda: Is that how it helps with epilepsy?
Dom: That's part of it. I think there's about 20 or more things going on if you look at all the signaling pathways [crosstalk 00:39:37] actually what happens, yeah, with metabolism, but I think a key player in that is an elevation of GABA to glutamate. And we need glutamate to make GABA, right, but the enzyme is elevated and the pathways are shift in favor of more glutamate to GABA, which has a stabilizing effect on your cell membrane and neural interactivity, in general.
Rhonda: How readily do ketones cross the blood-brain barrier?
Dom: It's thought up to five millimolar, maybe six, seven millimolar, they can readily cross the blood-brain barrier.
Rhonda: You have to get that high before they start crossing?
Dom: No they start impeding once you get levels up that high. It hasn't really been studied in-depth. We did brain metabolomics to show that when we looked at the ketone levels in brain tissue and ketone levels in the blood, and there's a high correlation there. Interestingly, we had a diet, too, that was high in medium-chain fatty acids. And although I heard the medium-chain fatty acids could readily cross the blood-brain barrier long-chain fatty acids typically don't, short-chain fatty acids sort of do. But we found very high levels of medium-chain fatty acids indicative of them and these were normal, healthy animals. So when you take medium-chain fatty acids, they are readily from the looks of our metabolomic data, just readily crossing the blood-brain barrier and capable of being used as fuel...
Rhonda: That's fascinating, I had no idea.
Dom: ...which is very, yeah, it's really interesting. I heard about that, but when you see the data it's at really high levels.
Rhonda: So when they're in the brain, then how are they...so then what happens? So they're used...
Dom: Yeah, their medium-chain fatty acids can be oxidized just like fatty acids for fuel, yeah...
Rhonda: Wow, interesting.
Dom: ..uh-huh... oxidative, but ketones are also very high in the brain and to really capture and understand it, you have to, sort of, capture the brain tissue really quick and freeze it and then do an analysis because the brain's using it as fuel after you take it, your brain's, kind of, still alive. Sort of, the step that I was showing you in the lab where we can take the brain out and cut it like a piece of bread and then record from it. So that brain is still active. So it, sort of, uses the metabolites. So to get a very clear snapshot of the difference in tissue versus blood is a little tricky as is getting ATP levels in the brain. It's a little tricky. We're working on that to be able to do that.
Another question which I think will involve radio tracers is actually to do, like, a ketone PET scan where we can look specifically at the regional distribution of ketones and figuring out what areas of the brain may be preferentially shuttling them and using them as fuel and how that may change under different pathologies, how that may change under oxygen deprivation, glucose deprivation, high oxygen, as I study oxygen toxicity.
Rhonda: Please look at genetic states like ApoE4 because that's one thing...
Dom: Yeah, that's a biggie.
Rhonda: Yeah, I'm very interested in some of this work you're talking about in ketone supplements helping with neurological disorders like Alzheimer's. It's been shown that that is dependent on ApoE status, and that just, it's disappointing to me because I really want to understand why and I just... Do you have any idea?
Dom: Well, so you're referring to the Henderson paper where they looked at...
Rhonda: Both papers.
Dom: ...Axona AC-1202? So the finding was in that study, which is relatively small, that at least not with the diet, but using a ketone supplement that was formulated with 20 grams of medium-chain triglycerides. So they gave to their patients, I think, just once a day. And they did show fairly convincingly that the elevation of beta-hydroxybutyrate correlated with an improvement in cognitive function, but that correlation was not observed in the ApoE4 positive group, which was a little bit...it was kind of surprising. I would like to see that study done using the ketogenic diet or maybe the ketogenic diet formulated with ketone supplementation. So, the question is...it did not have a negative effect, but the question is why didn't it have a positive effect?
Rhonda: Was there not another study where they actually did the ketone supplement, beta-hydroxybutyrate? I thought there was, but I could be mistaken just from my lack understanding because that would shed some more light.
Dom: Yeah, well, they used caprylic triglycerides, C8, which kind of makes a lot of ketones, relatively speaking.
Rhonda: Unless the ApoE is changing the way you're making ketones, right?
Dom: With fatty acids, yeah.
Rhonda: But they measured, you said they measured beta-hydroxybutyrate in everyone and the levels were the same because it's like I want to understand why there was no positive benefit in ApoE4 carriers because that's the one thing that...it seems so promising, right, that these ketone, potentially ketone supplements or a ketogenic diet can help modulate Alzheimer's disease.
Dom: Yeah, we...and I think you could do it in different ways. My student presented yesterday, she presented this week, but she graduated with her Ph.D. yesterday and her work showed that there's a remarkable increase in blood flow, and previous work has shown that ketone bodies can increase brain blood flow by 30% to 40%. So that's another, when you have vascular dementia, when you have a decreased, that being, staying in a state of nutritional ketogenesis...
Rhonda: Or just brain injury in general.
Dom: Yeah, it can have a profound effect.
Rhonda: Did she understand any of the mechanisms or do you know? Can you talk about it?
Dom: Yeah, we're looking at that. Well, we did ischemic wounds, which I mean, I guess you could kind of relate to an aged brain, right, with clogged arteries. We did a Doppler blood flow measurement and showed that it spiked up considerably when we can elevate ketones. One of the things, it was not dependent upon VEGF. So we looked at all the different factors, so VEGF was not increased in the wound. We looked at a couple of different other things that we thought would be increased. Well, the one thing that stood out in the data was adenosine. So adenosine levels are significantly elevated. Now adenosine is sort of thought to make us sleepy. You know, when we drink coffee, it's like an adenosine receptor antagonist.
Rhonda: No way.
Dom: There's high levels of ATP, sort of, being used and we think that they may be causing an elevation of adenosine, but we really have to delve into the metabolomics to understand why that's happening. Regardless, adenosine is a very powerful vasodilator, and it's in higher concentrations, significantly, in the blood and that may be increasing the profusion of tissues, peripheral tissues, and I think that was it.
Rhonda: That's great. Did it have any effect on blood-brain barrier at all as you look at that?
Dom: We haven't looked at that. My colleague has been, kind of, looking at that a little bit. We know with fasting and the ketogenic diet that you can increase permeability to the blood-brain barrier. Things get through faster.
Rhonda: You mean ketosis through fasting or both, combining the two?
Dom: Well, yeah, sort of, yeah, fasting-induced ketosis or even the ketogenic diet can help increase the permeability of the blood-brain barrier to a wide variety of things. So if you are, sort of, the implications from his perspective that if you're getting a chemotherapeutic drug, if you're getting some kind of drug that needs to cross the blood-brain barrier that's impaired in some way, you might be able to get that across faster in a state of fasting ketosis or the ketogenic diet.
So maybe if you're fasting maybe there's just less stuff in your blood, there's competition of things getting through and your blood's sort of clear and you introduce the drug and you get more rapid transport because there's co-transporters and other things or things that might be in their diet that may be impeding transport, there's multiple independent lines of evidence to suggest that being in a state of ketosis can help better transport things across, but when we talk about permeabilizing the blood-brain barrier, that's like a bad thing, right, making it more permeable. In general, though, you get a knockdown of neural inflammation from the diet and from therapeutic ketosis, which is something the epilepsy world is very interested in. So there's a PET scan technique that allows us to look at neural inflammation in the brain and we know that...this is a conference that I recently came from, that maybe an excellent predictor of when someone's going to have a seizure.
Rhonda: Yeah, that would be really cool to do. Possibly see if some of those effects remediated through this pentose phosphate shunt because glutathione in the brain is one of the major ways of producing inflammation, right?
Rhonda: So let's say you do this in an animal model and then you inhibit some of the pentose phosphate enzymes that are using glucose now instead to make NADPH and say, "Oh, is that mitigated?" Do you now not have that same effect? It'd be interesting to see if that's part of the mechanism because that's...
Dom: It's undoubtedly is, yeah.
Rhonda: Probably, right?
Dom: I mean, it's part of that and, sort of, plays into all that.
Rhonda: So I have another question for you. Thanks for, like, letting me jump all over the place because I'm super-interested in this and don't...
Dom: We need to follow up on the studies. So one of the studies we, sort of, we want to do, just following back up on that question, is where ketones are being metabolized and what their contribution is to normal brain energy metabolism and disease states and hypoxia states and traumatic brain injury. So that's a lot to do.
Rhonda: And those overlap, too, right?
Dom: That's the direction of where we're going with that research, is understanding that.
Rhonda: Just to jump back again before I ask you this other question to George Brooks' thing is that he's doing some interesting work working with some physicians at UCLA, I believe, with traumatic brain injury. So these are people that come out with, like, head gunshot wounds. And they are looking at infusing lactate because he's the lactate guy. But ketone bodies will work the same way.
Dom: I think it would work better from what we know.
Rhonda: Maybe even better.
Dom: Yeah, I think a cocktail of the two would be... And I've been debating whether or not to really study lactate sort of the same way I'm studying ketones and maybe make lactate esters or lactate and just to see what kind of results we see starting with our oxygen toxicity model and working from there, which is an excellent model.
Rhonda: Obviously, with the lactate, you have to have a intact blood-brain barrier because if no oxygen is getting there, you will get the lactic acid build-up, right? Because then, I mean, the mitochondria aren't going to be able to use the lactate, which is converted to pyruvate as energy, so it builds up, but he has been doing some work and looking at this glucose sparing in the brain. And in this, of course, ketone bodies would work very similarly, in theory.
Dom: Do you know how he gets...? Does he use, like, a lactate? There's alpha L-polylactate, I think. That's, like, in a sports supplement and some other thing.
Rhonda: He actually designed it...
Dom: Oh, really?
Rhonda: I think he's the one that, yeah, he's got a patent on that.
Dom: Oh, wow. I was using that back in 1991 and -two.
Dom: Cytomax, yeah.
Rhonda: That's him, that's his.
Dom: When I raced mountain bikes, that was, like, my go-to supplement, alpha-L-polylactate.
Rhonda: You should get in touch with George, he's great.
Dom: I know, wow.
Rhonda: So he... Let's see, what was I just going to say? I lost my train of thought.
Dom: The delivery or the...
Rhonda: Oh, yeah, so the delivery that he's doing...in this specific study, they're doing it intravenously, so. But I was mentioning the blood-brain barrier has to be intact, otherwise, it can go the opposite way where it's actually bad for you. But it would be really interesting to see so the question is, one, will this lactate or beta-hydroxybutyrate or whatever ketone get into the MCT shuttle better? So there's questions of which one gets in there? And can they be used together? And there's all sorts of interesting things, but I'm sort of interested in this for my own personal...
Dom: Yeah, the neuroprotective capacity seems really compelling. I mean, from what we know about lactate approaching it, going to back my old, like, PhD studies or whatever during hypoxia, but it would relate to so many traumatic brain injuries, hypoxia, so you're mitigating the damage from hypoxia.
Rhonda: Yeah, and also traumatic brain injury is inducing damage, and so, glutathione is one of the major ways of mitigating that. There's been studies showing that, early on, it's important. If you get that early on, it prevents the whole cascade so I think that ketones and lactate both seem to have huge potential for glucose sparing, but that, you know...
Dom: I think chilling the body and infusing ketones, lactate with a couple major few co-factors that are part of the bioenergetic use of these things would be a home run as far as...
Rhonda: Yeah, get some students on it.
Dom: Yeah, these are grants that I'm kind of working on and writing, but I'm not sure the funding agencies are ready to fully...they want, like, the magic pill thing.
Rhonda: So to bring it back to the magic pill, I'm kind of interested. So let's say someone like me that my diet is mostly, I eat a lot of plants, a lot of greens, broad spectrum, carrots, I eat a lot of vegetables. So I get a ton of fiber. I eat a lot of fish. And I do eat, like, beans, so I'm not adverse to legumes or even to oats. I like fiber. Let's say, I wanted to, I'm, like, super-interested in beta-hydroxybutyrate because I've been following a lot of the research from Eric's lab and I want to get some of those benefits. I want to increase my FOXO3. I want to reduce my lipid peroxidation, I want some of that signaling effect. Plus, I want to beta-hydroxybutyrate to be around to get to the brain, things like that. Can I potentially take a beta-hydroxybutyrate, whatever delivery source powder, pill, whatever it is, and potentially achieve some of those same benefits that you get from nutritional ketosis or ketosis from fasting? Let's say, but I don't eat a lot of, I don't eat refined carbs, so I'm not getting a huge insulin spike for the most part. So do you know?
Dom: So, yeah, you want to have your cake and eat it? But you don't eat cake, right?
Rhonda: But I don't eat cake. No, I just eat fiber.
Dom: You want to have your carbs. Yeah, that's that's really what we're working on right now and understanding in a head-to-head comparison to see if we can derive the same kind of benefits from ketone supplementation as we kind of with the ketogenic diet. We know the first kind of convincing studies of this that we did was with CNS oxygen toxicity in our rat model, and in that case, the rats were eating a high-carbohydrate standard rodent chow model, and we administered via an oral route a ketone supplement in the form of a ketone ester. That's probably one of the more powerful forms of exogenous ketones that we've developed. And that had the ability to prevent CNS oxygen toxicity from happening for almost, over 500% delay in that time to CNS oxygen toxicity. And that could not be achieved with fasting, it could not be achieved with anti-seizure drugs. So when it comes to enhancing and preserving brain energy metabolism in the face of a tremendous oxidative stress that breaks down brain energy metabolism, we're able to enhance that, preserve that. So we've also studied in our animal model of cancer, metastatic cancer simply giving ketones to the animals on a high-carbohydrate diet, it was almost unexpected the level of enhanced survival that we had with ketone supplementation.
Rhonda: What kinds of tumor is it?
Dom: This is a model of metastatic cancer and the primary tumor, it was derived from a glioblastoma, the GBM. And that tumor cell line is so aggressive that when it's injected or implanted into the flank of the animal, there's rapid systemic metastasis to all the organs and the brain. And the model that was developed by Professor Tom Seyfried at Boston College.
Rhonda: Didn't he publish a paper on...?
Dom: It made the cover of the "International Journal of Cancer." Yeah, when I wanted to this study initially, I wanted to do a brain tumor model, like with our diet and our stuff. He sort of wouldn't let me use the model. He's like, "Well, use this model of metastatic cancer because it's the most aggressive thing out there and no one will..." He's like, "If you create a cure, something that can cure this animal with metastatic cancer, you basically stumbled upon something that has the potential to cure cancer." So that, kind of, intrigued me. So I knew working with his model would be kind of difficult because the tumor burden...the animal has died so quick from the tumor burden, but it allowed us to screen a variety of things and just using this model understanding that in aggressive metastatic cancer, the cells are highly glycolytic, and they're highly in favor of using glucose and glutamine probably as an energy source. We're looking at ways to target glutamine, but have not really, kind of, implemented that yet in a combination therapy. But regardless, the animals are eating a high-carbohydrate diet with ketone supplementation and it reduced tumor growth and proliferation. We think that the ketones may be altering glucose metabolism.
Rhonda: They induce cell death?
Dom: Well, we think so. There's more, like, sort of, apoptosis in the tumors that were there, but just overall, there's just less tumor growth and less tumor burden and enhanced, most importantly, a 50% to 60% increase in survival time in animals that are supplemented with this. And it wasn't...although the animals tend to eat a little bit less if they're in ketosis, naturally, which makes a ketone supplement kind of an attractive thing for people that are dieting because when you're sending energy to the brain in the form of ketones, it has sort of a satiating effect on your body and it, kind of, shuts off that hypoglycemic trigger that makes you want to binge or crave food.
Rhonda: So is it changing ghrelin and leptin signaling, or...?
Dom: We think so. Yeah, we think so. That's the next thing to look at. It does impact the satiety centers of the brain. It's not like you don't want to eat, but you have control over your appetite.
Rhonda: You know what? I just thought of it. Lauric acid, which is C12, suppresses ghrelin in the gut, which is the hunger hormone... That's kind of interesting, right?
Dom: Is that specific for lauric acid?
Rhonda: It's specific.
Dom: I knew with certain fats. Really, lauric acid? That's interesting.
Rhonda: It is.
Dom: I'll look that up.
Rhonda: Sorry to interrupt. [crosstalk 00:59:39] Let's continue because this is really cool. So you fed them a normal high-carbohydrate diet, gave them this ketone ester, as we were talking about.
Dom: Ketone ester, the same ketone ester, which is.
Rhonda: The tumor burden was decreased, survival time increased.
Dom: Yep, yep. And so that was another demonstration, and the data looked very similar to the ketogenic diet. So we did the study.
Rhonda: They're eating less, you said, right?
Dom: They were eating slightly less, so we went back. We were thinking, "Well, maybe we're just getting a calorie-restriction effect," because if you have a mouse model or any kind of cancer model and you overfeed it the tumors are going to grow faster, and if you underfeed it you're going to restrict some of the tumor growth. So they were eating a little bit less, but a maybe only 10% drop in body weight. So we went back and we did a calorie-restriction control experiment, and although there was a decrease in tumor, it was nothing like the ketone supplement. So ketones we know undoubtedly they have anti-cancer effects, and it could be maybe through their expression of their gene expression as a histone deacetylase inhibitor. We think that they inhibit glycolysis. We think that they influence a number of pathways associated with cancer growth.
Rhonda: Did you measure mitochondrial respiration?
Dom: Of the tumor and the tissue or...?
Rhonda: Just, yeah, of, or any tissue, like, so let's say, did you give them ketones in this....
Dom: We looked at ROS production. Yeah, it can sort of knock down reactive oxygen species production.
Rhonda: In the tumor? Or in...
Dom: In normal tissue, yeah. And now it's kind of interesting, too, that in the tumor tissue in previous experiments, I showed that it could knock it down significantly, but I think in the paper that we published, there was a slight decrease in ROS production.
Rhonda: Yeah, that's interesting.
Dom: We don't know, we do...our experiments are sort of like a top-down approach. We find out what works and then, we're mechanistically going after it and we're doing -omics work metabolomic in particular, and western blots and assays. So now we're going after the mechanism, and if we understand the mechanism, we can, kind of, work backwards and tweak the molecule or adjust the diet in ways that may enhance the therapeutic effects.
Rhonda: It would be really interesting to do some of... I don't know if you can radio label these ketone esters and see if, like...
Dom: Yeah, that's another thing we'll look at.
Rhonda:...are they being used as a carbon source for ATP? Are they being used for something else, right, like...?
Dom: Tracer studies. That's what we want to do. Yeah, we're going to partner with a company that has, sort of, the market on doing these tracer fate associations. I think even doing a 13-Carbon glucose tracer fate association study where we give this, and we give ketones we look at the fate of glucose in the presence and absence of ketones and see how that may be influencing...
Rhonda: There you go, is it going to the pentose phosphate? I mean, this is all stuff I really want to know, so I'm, like, super-excited someone is doing it...
Dom: And I wanted to do this from the beginning, but I think we want to find out what works first and then now that we're identified, sort of, things that work with the diet and ketone supplementation, hyperbaric oxygen, I was telling you. We also study, we do a lot of metformin work. We have...I have one excellent Ph.D. student and Nate Ward, he's looking at the effects of metformin and on survival, tumor growth and doing a lot of the cell-based assays. And he's also looking at dichloroacetate, DCA. So it activates pyruvate dehydrogenase. So he's looking at each one, individual, and also in combination as a cancer therapy.
Rhonda: Okay, I'll give you some of my ideas. And so I, just because I want someone to test this. But with DCA, so I did a lot of work, in my graduate research, I did a lot of cancer metabolism I was in contact with Craig Thompson, Ralph DeBerardinis ... all those people that we were talking about earlier, and they did a lot of glucose withdrawal studies, glutamine withdrawal studies, blah, blah, blah, blah, like all that stuff. So I've got a lot of interest in it stemming back from years and years ago. And I also was very active in apoptosis, working with some of the top guys in the field, Doug Green. So I, sort of, like, the way I think about all of this and the intersection between them is that, like cancer cells are... Here's why I think cancer cells are glycolytic. So I mean, the Warburg effect you've talked about this and you published on it.
Dom: Is it a cause or a consequence? Yeah, damage respiration. That's sort of a...
Rhonda: Right, so I don't think...and I think even Otto Warburg himself published immediately after his original science paper because he originally theorized damaged mitochondria were the cause it, but then it's not. It's not that the mitochondria are damaged enough that they're not respiring. Even to this day, I don't think we have really shown that or disproven that, like, thoroughly. I don't think it's a cause, but the reason I think that cancer cells become glycolytic, I don't know what causes it or how, I think the reason is they do is because they don't want to use their mitochondria. And the reason they don't want to use their mitochondria is because mitochondria produce ROS, and that will drive... This is the whole basis of how you kill a cancer cell, chemotherapeutic drugs, the way they work is because they induce a little bit of reactive oxygen species toxicity through a variety of mechanisms.
Dom: Some more than others, but, yeah,
Rhonda: Right, through a variety of mechanisms...
Dom: Augment oxidative stress, yeah.
Rhonda: ...which then pushes the cancer cell to death because normal cells don't have boatloads of proapoptotic... If you look at any cancer cell, they have, like, boatloads of it. I mean, just tons and tons of proapoptotics, but they have countered it and they are ready to die. They just need a little push, and DCA activates mitochondria, and I think that's part of how...
Dom: Hyperbaric oxygen, too.
Rhonda: Hyperbaric oxygen, and we were talking about this earlier. I think that's also...
Dom: Naturally stimulate it, yeah.
Rhonda: Yeah. But so I'd like to see someone, sort of, test that because I think that possibly DCA wouldn't be as potent at killing cancer cells if you gave it NAC or something that's going to sequester the reactive oxygen species.
Dom: Yeah, so could you block it, yeah. That's another interesting, that would be a good control to do, yeah.
Rhonda: And studies have shown that giving mice supplemental vitamin E, something that's going to potently sequester reactive oxygen species, actually allows tumors to grow faster. And this has been [inaudible 01:06:35] in research.
Dom: Yeah, N-acetylcysteine, too, and NAC.
Rhonda: NAC, as well, yeah.
Dom: With metastatic melanoma, I think, came out, yeah.
Rhonda: Yep, yep. And then also there's one in lung cancer. I think it was the same group publishing that, too. But so I think that part of the reason...because cancer cells are so smart that I think that not having their mitochondria active is very beneficial to them because.
Dom: Or less mitochondria, too, as...
Rhonda: Yeah, less mitochondria.
Dom: So just a deficiency. And there's, yes, reports. So there's debate are the mitochondria defective or are there just a decreasing number of mitochondria? I think it's both. I think mitochondria are structurally and functionally impaired, and I think there's a deficiency of them.
Rhonda: You mean in cancer cells or [crosstalk 01:07:21] normal?
Dom: I think in cancer cells, but I think in just normal cells, if you if you're drinking alcohol and bombarding the liver with oxidative stress that you're damaging mitochondrial...you're damaging the mitochondria, and over time, you are going to...
Rhonda: Of course. Normal metabolism.
Dom: ...induce the Warburg effect by causing progressive damage, mitochondrial oxidative phosphorylation the cell's ability to maintain energy status through mitochondrial oxidative phosphorylation will be, its capacity will be impaired. So it will activate oncogenes and oncogenes that drive the glycolate. You'll have, some cells will die, the ones that survive are the ones that go on and activate the complementive genes that cause the transformation of a normal cell to a cancer cell. And that's how I, sort of, say that this progressive damage, you could do it with radiation, you could do it with chemotherapeutic agents, you could do it with inflammation, chronic inflammation is damaging respiration. And it's that damaged respiration that can kill off cells and the ones that survive, that are hardy enough to activate the genetic program that allow them to survive are kicking on the oncogenes that will then go on and produce a Warburg phenotype.
So that's sort of the metabolic theory of cancer in a nutshell. And it differs from what the thought leaders in the field are saying that it's more of default state to ensure the preservation of the cancer that that exists, but not the cause, but there's still this elusive enabling factor that we still don't know and I think the metabolic theory nicely explains is a pretty elegant explanation as to how a normal cell converts to a cancer cell. And there are other genes involved, definitely, but, I mean, at the very most, the most we can link hereditary effect to cancer is maybe about 10% 7%, I think, was a number that is being thrown around now, but about 10% of cancers are from hereditary, but this, the epigenetics, I think, is something that will, yeah...and that's something that's evolving very fast.
Rhonda: I mean, I think that DNA damage, and that's been pretty well-shown, damaging DNA, both mitochondrial and nuclear DNA, the damage that can lead to aberrant cells metab-, like, cells.
Dom: And I think the mitochondria are more important because the mitochondria have less of a robust DNA repair mechanism. And also the DNA of the mitochondria have more coding regions. So if you bombard cells with radiation classically, radiation biologists are taught that that radiation is directly damaging nuclear DNA and then that kicks on, causes the genomic instability that causes cancers, but I think what is being more appreciated now is that the mitochondria are selectively vulnerable because their DNA repair mechanisms are far less robust. They have much greater coding regions within their DNA, and they are the ones kind of calling the shots, they're making the energy, and if the energy status of the cell goes down, that's going to trigger the nucleus, that's going to trigger an energetic crisis in the nucleus, and the nucleus is going to kick on oncogenes to transform the cell from a normal to a cancer cell. So the stability of a nuclear genome is tightly regulated to the energetic state of the cell.
Rhonda: Yeah, so I have a little bit of a different way of thinking about it mostly because I'm also doing a lot of research on this experimentally. So I measure damaged DNA, and I measure mitochondrial function after I induce radiation in some sort of...
Dom: In primary cells?
Rhonda: In humans, in blood cells, yeah. But so, mitochondria, you mentioned that nuclear, they have more repair mechanisms, and that's true, but mitochondria have very elegant and beautiful way of repairing damage through fusion, right, mitochondrial fusion and fission. And this is a process, I mean, this is how we are able to repair damaged mitochondria because they're constantly fusing with healthy mitochondria changing, I mean, exchanging their DNA content, protein, things like that, and fissing back part. So, of course, when those mechanisms become impaired, then that's, we start to have more accumulation of damage more because they can't repair.
Dom: Fission proteins, the production of the proteins that cause that are also tightly linked to oxidative stress.
Rhonda: Yeah, so I mean there's lots of different ways to repair damaged mitochondria. I also did a lot of work in graduate school. But I don't think it's clear, I don't think that the metabolic theory of cancer...
Dom: Far from clear.
Rhonda: You know, when you drop the ATP status in the cell, what happens is the cell dies and apoptosis gets trigger, and that's the primary...before oncogenes are activated, the cell dies.
Dom: Unless it's if it's more gradual, then you have the activation. And most cells die. So you have 999 cells die and then you have one that, kind of, activates the complement of genes that can, allows it to survive, gives it survival advantage. That's what you get with chemo, too, or radiation when you blast a tumor with radiation. You get, there's few that can survive. And if you do that over and over to the tumor or over the course of chemos, you're kind of making a super-cancer because you're increasingly selecting for the most aggressive, glycolytic hardy stem cell-like tumor cell by hitting it with more chemo, you're just causing more DNA damage and more transformation, mutagenicity. Do you see it like that?
Rhonda: I don't know.
Dom: I'm not against standard of care, but I'm in favor of.
Rhonda: I wanted to believe, in graduate school, I wanted nothing more than to believe that mitochondrial dysfunction is the cause of cancer, but I just couldn't, just couldn't attribute to myself. You know, I kept trying and trying, it would have been easier for my graduate... My graduate career would have been shorter, for one, but I just couldn't enough evidence to convince myself of it. And that doesn't mean that it doesn't, it's not true, it just means, I just...so far don't...I don't think that's the origin of cancer. I think that metabolic dysfunction plays a very important role in causing cancer. Most primarily through inflammation through all the effects of, like the insulin signaling and the inflammation, the reactive oxygen species. All these things that are damaging the cell, but I don't necessarily see it the way that you, sort of, described it as them...
Dom: An initiator.
Rhonda: Yeah, them changing or activating oncogenes. I don't think that's really been shown.
Dom: I don't think anyone's studying that because...or studying it in the way that would make it clear, and I think it may vary between cancers like leukemia and lymphoma and relative to glioblastoma. I mean, we know these are just, they have a different metabolic and a different gene signature. Glioblastoma has hundreds, if not thousands, of genetic mutations. You know, so hence the name glioblastoma multiforming, you have all these different cell types and everything. Whereas other types of, like, for leukemia, for example, Gleevec works marvelously well because it's targeting something that's very specific. So I think it will be impossible to get a clear answer to this and I don't think it's... I think maybe I'm a centrist. So I'm somewhere in between the genetic versus metabolic, but leaning more towards a metabolic origin for many solid tumors, but there's some cancer that just, kind of, throw me a curveball like different types of lymphoma and leukemia, testicular cancer. And they're all responsive to chemo, many of them are.
Rhonda: So what about, like for me, when I think of mitochondrial dysfunction, to me, that leads more to neurological dysfunction, neurological disorders, less for cancer, less of cancer like when you...mitochondrial mutations, genetic mitochondrial mutations in mitochondria genes, there's much more it has much more of an effect on causing certain types of neurological disorders rather than, like, cancer, right? There's one, I think, the succinate dehydrogenase complex II, one of the components. I know this because I was trying to figure this out in graduate school, it was, like, a huge question.
Dom: And the really bad diseases, yeah, these mitochondrial disease, yeah.
Rhonda: So that's what I usually think of, when I think of mitochondrial dysfunction, I always think of it as being more of a, playing a causal or initiating role in neurological disorders and neurological dysfunction, and not so much as, plays a role. I think that mitochondrial dysfunction and abnormal metabolism plays a role in cancer, but I don't think it's that initiator the way you were describing it. I just don't think that's been shown.
Dom: I'm going to prove you wrong. Well, our lab is we're not, we're just trying to find the answer. And I think that as we move forward and develop the tools, I think the answer will start to get a little bit more clear at least using the models that we're using. But I think regardless even of the origin...the origin is important because if we...the way we treat and prevent cancer is going to be different if we know the origin for sure. You know, if it is a mitochondrial versus genetic origin or whatever origin. And, I mean, there's a case for viral origins of cancer, too, but these viruses are, sort of, the ones that damaged mitochondria, too. I've been, sort of, interested in the viral origins of cancer.
It will influence how we prevent cancer. So in addition to developing therapies, we want to study animal models, and maybe inducers of carcinogenesis and then adapt them, or to treat them prior to, or put them on a therapy prior to letting them live out their lives if they're prone to spontaneously forming tumors, or letting them live a few months prior to the introduction of a carcinogenic agent, and then seeing after X amount of time, whether the tumors form. So can we prevent this does have profound implications for people who have been, went through chemotherapy or had cancer in the past, and should they be on some, kind of, preventative, should they do a therapeutic fast? I get this question a lot for four or five days to a week every two or three times a year. Should they do that? Will it help them purge their body of pre-cancerous cells and put that metabolic stress? And these are important questions that no one is really trying to answer at least from a point of a prevention, sort of, idea.
So I think that's sort of on my horizon as the next big thing. Can we develop and implement have these protocols available for someone to do? It could be intermittent fasting. I personally like ketogenic intermittent fasting, where you're taking in ketogenic fasting, ketone supplements throughout the day and through 20 hours of the day and you have a 4-hour window where you eat a well-balanced ketogenic meal that's rich in vegetables and high in fats and protein. And I think that could be something that could be implemented and something that I personally am interested in writing up a protocol for that.
The work, the studies done with metformin and showing that people who, type 2 diabetics that are taking metformin have a 62% less chance of getting pancreatic cancer. We need to study that, you know? Should that be a part of a comprehensive preventative therapy that people should do? I mean, I question, should I have my parents on this? Like, should they, you know...?
Rhonda: On metformin?
Dom: Or yeah, on metformin, or my mom actually had cancer years ago. Should she be on something like this? Should everybody be after the age of 50 if most of their family members have died of cancer?
Rhonda: Have there been any long-term studies on the effects of metformin? Because I'm very interested in it, but I'm always hesitant with any drug or anything that's perturbing biological systems.
Dom: Yeah, well, there's hundreds of thousands, if not millions, of people on metformin so I'd say, yeah, there's a long-term data out there whether...and a lot of retrospective studies have been done. It's a relatively safe drug. Lactic acidosis could be a problem in higher doses for some people maybe with renal insufficiency or impaired liver function. And then, another thing that creeps up could be vitamin B12 deficiency. So if you are...our ability to absorb vitamin B12 as we age is decreased, so maybe a sublingual form or even B12 injections in people that are older?
Rhonda: Why does metformin affect B12?
Dom: That's a question I don't know an answer to, but I can speculate that it may influence the transporter, and it also tends to make stools loose for some people. Things go through you a little bit faster and impairs... "Impair" is not a good word. It changes the gut microbiome favorably. So "Nature"....the paper there's that came out about two weeks ago showing that there's a favorable shift in the gut microbiome...
Rhonda: Now the reason why it's interesting.
Dom: ...with metformin, and that may explain it's type 2 diabetic it's glucose-lowering effects. That sort of hit me as, "Wow, I had not really given that a whole lot of thought, but it's something that I think we should be looking into." So I was like, "Yeah, we need to collect all the start collecting the feces from these animals that we're doing metformin on to figure out what's going on with the gut microbiome," but I think it's influencing the absorption of B12 in some way that I don't really know.
Rhonda: Does metformin...is it doing anything in addition to mimicking a lot of the same signaling pathways that caloric restriction does? Like, is there something additional that...you know?
Dom: Yeah, yeah, AMP kinase, for sure. So without a doubt, I mean, it's mimicking many of the pathways of associated with calorie restriction and with fasting. To what degree it's mimicking that relative to a length or duration of fasting? I don't know. We're doing some work right now looking at AMP kinase and mTOR, and downstream and upstream signaling insulin and these things, and trying to get a picture of this, at least in a rodent model. And then, I'd like to ultimately replicate some of this stuff in humans, but what I think, I think metformin would be best used maybe in pulsing it a few times a year. A lot of these things, metabolic interventions tend to work best when you cycle them, I think. And I really have not been doing that, but I think it's a theory that I have been working on. I need my scrapbook.
Rhonda: Why do you think that is?
Dom: Because your body is similar with ketoadaptation that your body can, kind of, reset to that level, initially fasting on the ketogenic diet is sort of a stress and it can induce a hormetic effect in gene transcription and then we, sort of, get used to that. You know, our gluconeogenesis is upregulated to that level, but I think it's good to maybe pick probably not a high-carb diet, but maybe a Paleo diet a low-carb ketogenic diet and maybe something in between and do some intermittent fasting on occasional days. So I think this promotes metabolic flexibility. It allows our body to adapt to different situations without being, kind of, overwhelmed by the stressor of it. So I think, to some extent, it is hormesis. And interestingly, metformin causes mitochondrial stress, and actually, mitochondrial damage. Some researchers coined the term that it's stimulating reactive oxygen species production and causing mitochondria dysfunction, metformin is, and this is kind of well known in the field. So the general feeling is that, "Well, if I take metformin and I go exercise, why is it not killing my exercise capacity or my VO2 max or making me lethargic or tired?" It's not doing that, actually I think it's enhancing. There was a [crosstalk 01:25:34] study.
Rhonda: Does it affect biogenesis?
Dom: It does. So yeah, so the thought that it's kind of stimulating, there's a hormetic effect. It's damaging the mitochondria, some people believe this, and you get a secondary, yeah, effect through that way, like it's, kind of like an exercise drug. But I approached it from the perspective that metformin could lower blood glucose at least if it was high and it activated AMP kinase, and it may decrease circulating insulin. So I approached it as a cancer drug from that perspective, but the more conferences we go to, there's a plethora of data coming out of metformin and a lot of people are studying it from the perspective of impaired complex I or complex II activity in the mitochondria. So they're looking at it from that perspective.
Dom: I know.
Rhonda: Yeah, it's super interesting. Especially, you're giving its effects on longevity and cancer.
Dom: Yeah, yeah, and I think our most recent data did show an increase in ROS production in our cell line.
Rhonda: I wonder if that's how it's also killing the cancer cells.
Dom: Yeah, it could be.
Rhonda: You mentioned when you were talking about gluconeogenesis, you triggered something in my mind. I wanted to ask you, I forgot. So when you're in nutritional ketosis or fasting-induced ketosis, you need to make glucose you still need glucose, your red blood cells have no mitochondria and your red blood cells are important, right? So you're making glucose through this process that you mentioned called gluconeogenesis.
Dom: Glucose does not bottom out. It's not like one or the other. You're pulling fuel source from...
Rhonda: So I wanted to ask you about, like, how... Has anyone looked at where...so if you are on a pretty strict ketogenic diet or whatever it is you're doing to get into ketosis, what...so does the liver use, like, glycerol, lactate, like, both as a primary source to make glucose? Is that glucose predominantly going to red blood cells or does it go has that been looked at to see, like, where, you know...? So red blood cells, like, are they getting enough of their glucose or they, you know?
Dom: I think so. I mean, you'd probably have to severely calorie restrict. In those cases, you could become anemic or impair...your immune system is also, too, highly dependent to some extent on glucose and glutamate. So, yeah, you have lactate, you have the glycerol backbone, the fats...
Rhonda: But they always have mitochondria.
Dom: Yes, yes. So glycerol backbone of fatty acids or of triglycerides, for sure, lactate, yes, and amino acids, gluconeogenic amino acids in your diet also are a source of glucose. So gluconeogenic amino acids in your skeletal muscle your muscles constantly breaking down or remodeling especially in athletes. So they're all sources.
The contribution of each of these gluconeogenic sources in each individual probably varies tremendously, but I would say that... So glucose is always going to be there, and the body ensures through very powerful homeostatic mechanisms that your glucose is going to stay, rarely go below three, maybe 2.5 millimolar, mine will drop two, go to four and stay within a very tight range, but what does change considerably from a glucose regulation standpoint is the insulin.
Insulin bottoms out to the point where I've seen enough blood work to show that in many cases, insulin and IGF-1 is below the reference range. So insulin signaling goes down. So if insulin's down, all those insulin pathways that you see on your flowcharts are all going to be suppressed and IGF-1, obviously, it's going to be lower and I think that's a really important consideration to factor in as it relates to cancer therapeutics, cancer biology, cancer prevention, even. But also from the perspective of muscle metabolism. And I think by keeping insulin signaling sort of low, you upregulate factors that make you more responsive to insulin. So I think, and ketones can kind of compensate for a deficiency in insulin, and that was, a lot of the reviews by Richard Veech talked about that.
And the ketones themselves are anti-catabolic for protein sparing. So if you're in a state of ketosis, you're protecting gluconeogenic amino acids and skeletal muscle from being degraded. So you are as a metabolic fuel, but you're also, there's evidence that you're inhibiting proteolytic enzymes and pathways that would otherwise be chewing up your muscle tissue over time.
Rhonda: That's super-cool.
Dom: So it's anti-catabolic, yeah, so ketones are anti-catabolic in that part.
Rhonda: So then you're probably not using, I mean, the gluconeogenic amino acids as much...
Dom: From skeletal muscle, yeah, not as much. So the idea is that you want to keep pumping in the fat, too, if you're on a ketogenic diet. If it's not sufficient with ample amounts of fat, you're probably much more catabolic. So you want to ensure that you're using the fatty acids, go to the mitochondria that uses fuel, they keep the mitochondria happy as do the ketones. Then the glycerol is kind of,shuttled and it's a very nice kind of an elegant pathway to ensure that we have that flux of glucose for vital functions like the red blood cells and making...there's an number of neurotransmitters and hormones that require a baseline level of insulin or glucose to be used.
Rhonda: Yeah, and we talked about...
Dom: A lot of things, yeah.
Rhonda: Yeah, it's just so many things to discuss, but I'm really, like, thankful that you...
Dom: We can probably talk for, like, four or five days non-stop before we like collapse from...
Rhonda: You see how I get, I get, like, really excited and I'm like, "Okay, wait, I got to ask you this question. I have this idea." And then you're just, like, full of information. So it's kind of neat.
Dom: A fun field to be in, right?
Rhonda: Totally, I guess.
Dom: I mean, I'm always, I feel like I'm so lucky to be in an area of...be in an occupation where discovery, we have the potential to discover something new that can impact the population and get paid for it.
Rhonda: Okay, that part, I get. Because you totally, I'm sorry to change the subject, but you're talking about glutaminolysis and I have done a lot of research on this, and there are questions that I would love to be answered, but haven't been. So, since you're looking at this and you have resources, I'll just throw it out there. Obviously, you said this is well-known literature that glucose and glutamine are both source...cancer cells love them. It's like crack for cancer cells, both glucose and glutamine, and I've done a lot of studies on various types of cancer cells and these are in vitro. So this is not in an animal model where I can, I withdraw glucose and the cancer cells will proliferate slower, some will die, but if there's glutamine there...
Dom: What's your level of glutamine?
Rhonda: Two millimolar.
Dom: Two millimolar, yeah.
Rhonda: Yeah, so then I would start withdrawing the glutamine and glutamine withdrawal, this is all in vitro, though. Glutamine withdrawal would kill them within 24 hours, but.
Dom: Pretty lethal, yeah.
Rhonda: Very lethal, and has been shown at least some of the studies that were initially done by Ralph DeBarardinis when he was with Craig Thompson, and later when he established his own lab where he radiolabeled and showed that, actually, it was being used predominantly for macromolecular synthesis and not for which is...of course, that makes sense because a lot of tumor cells aren't using the mitochondria.
Dom: Making fatty acids, actually.
Rhonda: Making fatty acids, proteins, like, for new synthesis.
Dom: Like, cell membranes and stuff.
Rhonda: Right, so the question for you...the question that I have and this is... So that's one of the spectrum. Okay, glutamine seems bad when you're looking from an in vitro perspective and I did these studies, but many people have published on this. You're familiar with the literature. But then there's the other perspective where really glutamine really is believed, like, to gut, to cells, it's very, very healing and therapeutic for gut, and when you take glutamine orally, the gut takes it, it's not getting into your bloodstream, It's not being so...
Dom: The gut and the liver take its share and very little of it actually gets into the bloodstream.
Rhonda: Right, so that's what I'm getting at. The question is, if you have a mouse model of a solid tumor that's not gut-oriented, so it's not colon cancer, like let's say it's you got a pancreatic cancer or...
Dom: Brain tumor.
Rhonda: ...brain tumor, then you give the mouse glutamine, is that really is it really going to affect the tumor or is it just going to help the gut? I mean, of course, it can indirectly affect it, but the question for me, in my mind, is, well, yeah, if you had tumor in the gut, man, that's like crack for the tumor. Do not take glutamine, do not, you know... But on the other hand, if you've got gut issues, you know...
Dom: It can be helpful.
Rhonda: Right, do you see what I'm getting at?
Dom: This is something that I have thought about.
Rhonda: You have?
Dom: Yeah, I think about stuff like this, yeah.
Rhonda: I'm not alone, yeah, well, in vitro is very different because the way our bodies are working and the way glutamine when we take glutamine, it's affecting our gut, it's very important. I mean, it helped. It's helped me.
Dom: I used to take it.
Rhonda: It's helped me with gut, but then there's this whole, like, conflict in my head around...cancer cells love it, but the question is if I'm taking it orally, and I have some cancer cells, in my, I don't know, my liver or something, then I guess you said liver is one that does. it does use it, but, so the question is, is that harming me or is it helping me?
Dom: Should you take it or not? Yeah, I get that question a lot. For GI cancers and liver cancer, I would say do not supplement glutamine, and I would say under most conditions...I always say in those states, I actually tried to look up the glutamine content of food, and you might want to avoid it or minimize glutamine, high glutamine-containing foods. Otherwise, I wouldn't really pay too much attention. Some patients really stress out about it but I think if you just keep your protein low to moderate, or keep your protein at a level to ensure proper regeneration and just, kind of, replenishment of your normal cells, and prevent protein deficiency, and being in a state of ketosis will help with that to some extent, but glutamine is pretty low on...
Rhonda: The classical ketosis, right, where it's 10% protein?
Dom: Yeah, yeah, and I think that will lower your blood glutamine levels, just being on a ketogenic diet will do that. And then, you could further lower it by selecting protein food sources that are lower on the end of, are glutamine. I'm not for avoiding protein types of supplements, avoiding glutamine supplementation all together. And you may be able to further suppress glutamine by taking a supplement that's like high branched-chain amino acids, high essential amino acids. So taking a supplement that is formulated in a way that, kind of, gives you essential amino acids, excluding glutamate, of course. Glutamine is not an essential amino acid. It's conditionally essential. But then you...I don't think you'll run the risk of being deficient in glutamine in any way, but I would avoid, I would pay attention to it if you have a GI cancer or liver cancer, and then if...
Rhonda: The liver, I didn't know, but yeah, GI was...
Dom: So if you have, say, for example, like, a brain tumor and you're taking a drug that can impair systemically, you're taking something that impairs your GI function, and it may be helpful to take a little bit of glutamine because I don't...I really don't think...the gut's going to be very greedy when it comes to glutamine.
Rhonda: It's very greedy.
Dom: So I think just maybe even 5, 10 grams of glutamine to help repair your gut. We know that if your gut permeability is impaired, that can wreak havoc in your body as far as systemic inflammation. So try to...and there's other ways to repair your gut, too, but I think glutamine may be a factor in helping to ensure proper gut.
Rhonda: Yeah, there's definitely other ways. I mean, I think that you know, like I was saying, fiber, good diet, and things like that.
Dom: Exactly. But glutamine has been used in oncology. So, yeah, glutamine is for helping people with chemo combating the issues with chemo. And then glutamine has almost been like a staple, you know...
Rhonda: So they give it to chemo patients, kind of...
Dom: Help them recover part of the immune system, too.
Rhonda: Because your gut regulates the Immune systems well.
Dom: Your gut is, like, what, 70%, 80% of your immune system, right? So it's huge. So we want to keep your gut as healthy as possible. And there are many drugs out there that really impair gut mobil-, or...
Rhonda: And diets, too.
Dom: Yeah, and diets, too.
Rhonda: Yeah, so, cool. All right, Dom.
Dom: Endless amount of things we can talk about, right?
Rhonda: I know, right. Just keep going, Dom.
Dom: Yeah, I've had, like, 100 things pop into my head. I was like, "Should I bring that idea or should I not? No, no, no."
Rhonda: Bring it up, I'm always interested in new things, so...
Dom: We do have ketone esters here and not too many people are brave enough to try them, but we have a lot of studies going on using a wide range. See, they're all different types of ketone supplementation, and I know that's, kind of, was like one of your main interests that you wanted to hit on.
Rhonda: Yeah, yes.
Dom: And I would say stay tuned because we have so much going on right now with, like, all these studies looking at ketone supplementation and the answer that I want to really focus on is what, kind of, benefits are we deriving? There's been so much work on the diet what kind of, benefits can we mimic with just purely a ketone supplementation? And can we further augment the therapeutic efficacy of the ketogenic diet with supplementation? So with diet and then we supplement 10%, maybe 20% of the calories with some form of ketone supplementation. Hopefully. we work to formulate it in a way that makes it pleasurable to taste and not taste like gasoline, if we can do that.
Rhonda: Does it taste really like gasoline?
Dom: Yes, yeah, like jet fuel, really. It's pretty bad, but the ketone esters do, but we're working on the ketone salts that you might know of, KetoCaNa, ketone, there's a couple ketone products out there.
Rhonda: Are there benefits or drawbacks taking one or the other?
Dom: The salts are like as far as ketogenic potential, are pretty similar to MCT. So they're another level up from MCTs, I would say right now, but they're being formulated. We're formulating them and testing them in ways to make them closer in potency to the ketone esters. And I think...
Rhonda: Are these available, like, to consumers?
Dom: Not for human use yet, but we're working on doing all the safety studies and then all the palatability work and formulating them in a way that probably within the next six months to a year, that they will be out.
Rhonda: Oh, so soon?
Dom: We're tracking them for therapeutic purposes. So for clinical trials, for specific diseases, and then, they kind of work backwards to the consumer broad market eventually. But, and for oxygen toxicity, obviously. That was the original application for oxygen...
Rhonda: Yeah, I'm also really interested in it just for movement disorders. My mother has orthostatic tremor, and she's not the kind of person that is very compliant. I mean, she may try something for, like, a couple of days, maybe a week.
Dom: That's typical.
Rhonda: Very typical, and drives me crazy because I feel like I have so much knowledge, I could help her, and it's just very hard to get her to do, to get any movement, but I would...I'm very interested in the potential use of ketone esters or whatever delivery method that's the best in potentially helping reduce her tremor because when she stands still, her legs shake and it's very, it's inhibiting to her life, I mean having to... When she's walking, I mean, she's fine, but if she stands, stands in line...
Dom: From sitting to standing, and just...
Rhonda: No, even walking to standing, just standing. So standing still, it's called orthostatic tremor, and it's common enough...
Dom: Yeah, yeah, I've heard about it.
Rhonda: ...that, but it's not like, it's not as common as essential tremor, but she also has essential tremor, as well, [crosstalk 01:43:13] kind of interesting. Yeah, so I'm extremely interested in the potential benefits of nutritional ketosis, yes, but, like I said, she's not very compliant. So I'm, sort of, like, okay possibly giving her some sort of ketone ester see how that would affect...because then again, if she...
Dom: You might want to start with MCTs. I mean, something, what I showed you today, the MCT Powder by Quest Nutrition is really pretty close it's very potent from a ketogenic perspective and if you were to take four to six to up to eight scoops a day, which would be tolerable in a course of a day, she would be in a mild state of ketosis and would be getting the benefits from it.
Rhonda: Really? Do you think that would be easier than, like, the MCT oils?
Dom: From perspective of GI tolerance, yeah. Many people I would say up to 40% or 50% of people are going to have some tolerability issues with liquid MCTs. At least a big dose that gets you up into sustainable ketosis. You can incorporate MCTs in your food, even salad dressing is cooked with it, mix it in with different things, but the MCT powder I found was, is you can get levels about twice as higher than you can with the oil just simply because your GI tolerance is much better in a powder form. So it's formulated in a way that, kind of, allows us to sustain the slower release of the MCT instead of a liquid which tends to...some people just can't tolerate the liquid at all. I can tolerate fairly high amounts relatively speaking, but I could tolerate much higher amounts with an MCT powder.
Rhonda: You can put it, like, and you can mix it with water, coffee, tea or whatever.
Dom: Yeah, I could put it in coffee.
Rhonda: Yeah, [inaudible 01:45:05]..
Dom: Yeah, and you liked it, right?
Dom: I mean, it's like great.
Rhonda: It's like creamer, but, you know.
Dom: So they really nailed that product.
Rhonda: The coffee makes her tremors worse so she doesn't drink caffeine.
Dom: No stimulants, yeah. What about decaf coffee or something like that?
Rhonda: Um, I think she...
Dom: It's a good vehicle for MCTs. I mean, you could put, like, butter and MCT. I know you don't like sweeteners, but I just put in a little pinch of stevia in there.
Rhonda: Stevia is okay.
Dom: And it makes it a really enjoyable drink for me.
Rhonda: Yeah, that's great that it's available because I'm, kind of...that would be something that we probably try, seeing if that has any effect on her tremors.
Dom: As you know, diet is key, though.
Rhonda: Diet is key, yeah, because if you're, like, eating a bunch of refined crap and processed foods, and just terrible diet, it's not much that ketones are going to do. Right?
Dom: Yeah, and what I find in people that are resistant is that if you can introduce foods that replace other foods which is good, and I think Quest Nutrition, too, is making a line of... they're not out yet, but I've tried everything from a ketogenic Oreo to a ketogenic brownie to ketogenic chocolate bars. So these are foods that when you eat them, you're in ketosis, and they taste as good or good as their high-sugar counterparts that are on the market.
So I see that as almost like the next frontier, like, designing, developing ketogenic food products from whole food ingredients that are from natural sources and not synthetic sweeteners or artificial flavors and things like that, that will allow you to...will ensure greater compliance of nutritional ketosis. Mainly at first, maybe targeting disease populations, but undoubtedly people from all walks of life will be wanting to use these foods especially if they taste good. And I can tell you from kind of a beta tester point of view that it is possible to create a line of food products from crackers to chips to, you name it, really. It's possible to...it's pretty easy to make something taste good when you're working with fat because fat has...fat and salt kind of make things, are really good on our palate. And they're very satiating. So we'll eat it a little bit, and it's just enough to sustain us and give us the energy that we need without overeating.
Dom: So I'm excited about the ketone supplements, obviously, but I'm excited about a line of ketogenic diet food products that can ensure compliance in people who really need it. Because I say that's where...there are people who know the diet would help them from a therapeutic standpoint, but they just lose interest after trying to follow through with the diet.
Rhonda: Yeah, and it would help eliminate a lot of suffering especially for some of these people with these, like you said, drug-resistant seizures.
Dom: Yeah, for sure.
Rhonda: That, so, yeah. Well, super-cool, Dom. Thanks for speaking with me and for doing all this really cool research. I'm going to keep following your researching.
Dom: Thanks for visiting.
Rhonda: If you want to learn more about your research, what you do, things you talk about anything related to your research, where can we hear more about you?
Dom: I would say I'm working on a more interactive, but broader site, but for right now, ketonutrition.org, I think, would be the site to go where I compile a bunch of links on there with dietitians, ketogenic-savvy, registered dietitians that I recommend, books, talks from IHMC, which I'm excited to listen to your IHMC talk this week because that's on there. So I would say that ketonutrition.org would be the site...
Rhonda: Ketonutrition.org. And what about social media, do you have any?
Dom: Yeah, Facebook. You can find me on Facebook, on Twitter, LinkedIn, Pinterest, maybe I go there sometimes. But Facebook, Twitter, and LinkedIn are sites where I will post information about our research or related research in the area of nutritional ketosis and metabolism.
Rhonda: Awesome. Thanks a lot, Dom.
Dom: Thank you. Thanks for having me.
A purine nucleoside composed of a molecule of adenine attached to a ribose sugar molecule. Plays a role in regulating blood flow to various organs as a vasodilator, and, in its role as a neuromodulator, adenosine is believed to promote sleep and suppress arousal. Adenosine is also involved in energy transfer as ATP and ADP, and signal transduction when in the form of cAMP.
Adenosine Triphosphate (ATP)
An energy-carrying molecule present in all cells. ATP fuels cellular processes, including biosynthetic reactions, motility, and cell division by transferring one or more of its phosphate groups to another molecule (a process called phosphorylation).
AMP Kinase (AMPK)
An enzyme that plays multiple roles in cellular energy homeostasis. AMP kinase activation stimulates hepatic fatty acid oxidation, ketogenesis, skeletal muscle fatty acid oxidation, and glucose uptake; inhibits cholesterol synthesis, lipogenesis, triglyceride synthesis, adipocyte lipolysis, and lipogenesis; and modulates insulin secretion by pancreatic beta-cells.
Amyotrophic Lateral Sclerosis (ALS)
A progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
Apolipoprotein B (ApoB)
The primary apolipoprotein of chylomicrons, VLDL, IDL, and LDL particles. Apolipoprotein B is produced in the small intestine and the liver. It transports fat molecules (such as cholesterol) to all the body's cells and tissues. High levels of ApoB, especially when LDL particle concentrations are also high, are the primary driver of the formation of plaques that cause vascular disease.
Apolipoprotein E (ApoE)
A lipoprotein produced in the liver and the brain. In the brain, ApoE transports fatty acids and cholesterol to neurons. In the bloodstream, it binds and transports cholesterol, bringing it to tissues and recycling it back to the liver. Approximately 25% of people carry a genetic variant of this lipoprotein called ApoE4, which is associated with higher circulating levels of LDL cholesterol and a 2- to 3-fold increased risk of developing Alzheimer's disease.
Programmed cell death. Apoptosis is a type of cellular self-destruct mechanism that rids the body of damaged or aged cells. Unlike necrosis, a process in which cells that die as a result of acute injury swell and burst, spilling their contents over their neighbors and causing a potentially damaging inflammatory response, a cell that undergoes apoptosis dies in a neat and orderly fashion – shrinking and condensing, without damaging its neighbors. The process of apoptosis is often blocked or impaired in cancer cells. (May be pronounced “AY-pop-TOE-sis” OR “AP-oh-TOE-sis”.)
Star-shaped cells found in the brain and spinal cord. Astrocytes facilitate neurotransmission, provide nutrients to neurons, maintain neuronal ion balance, and support the blood-brain barrier. Astrocytes also play a role in the repair and scarring process of the brain and spinal cord following traumatic injuries.
The tendency for something to promote the formation of fatty deposits called plaques in the arteries.
An intracellular degradation system involved in the disassembly and recycling of unnecessary or dysfunctional cellular components. Autophagy participates in cell death, a process known as autophagic dell death. Prolonged fasting is a robust initiator of autophagy and may help protect against cancer and even aging by reducing the burden of abnormal cells.
The relationship between autophagy and cancer is complex, however. Autophagy may prevent the survival of pre-malignant cells, but can also be hijacked as a malignant adaptation by cancer, providing a useful means to scavenge resources needed for further growth.
A chemical produced in the liver via the breakdown of fatty acids. Beta-hydroxybutyrate is a type of ketone body. It can be used to produce energy inside the mitochondria and acts as a signaling molecule that alters gene expression by inhibiting a class of enzymes known as histone deacetylases.
A highly selective semi-permeable barrier in the brain made up of endothelial cells connected by tight junctions. The blood-brain barrier separates the circulating blood from the brain's extracellular fluid in the central nervous system. Whereas water, lipid-soluble molecules, and some gases can pass through the blood-brain barrier via passive diffusion, molecules such as glucose and amino acids that are crucial to neural function enter via selective transport. The barrier prevents the entry of lipophilic substances that may be neurotoxic via an active transport mechanism.
Branched-Chain Amino Acids (BCAAs)
An amino acid having aliphatic side-chains with a branch (a central carbon atom bound to three or more carbon atoms). Among the proteinogenic amino acids, there are three BCAAs: leucine, isoleucine and valine.
The practice of long-term restriction of dietary intake, typically characterized by a 20 to 50 percent reduction in energy intake below habitual levels. Caloric restriction has been shown to extend lifespan and delay the onset of age-related chronic diseases in a variety of species, including rats, mice, fish, flies, worms, and yeast.
The process by which cancer is initiated and normal cells are transformed into abnormal cells. In order for a normal cell to transform into a cancer cell, genes that regulate cell growth and differentiation must be altered. DNA damage is a well-known initiator of cancer because it can lead to cancer-causing mutations.
The set of metabolic pathways that breaks down molecules (such as polysaccharides, lipids, nucleic acids and proteins) into smaller units that are either oxidized to release energy or used in other anabolic reactions.
A broad category of small proteins (~5-20 kDa) that are important in cell signaling. Cytokines are short-lived proteins that are released by cells to regulate the function of other cells. Sources of cytokines include macrophages, B lymphocytes, mast cells, endothelial cells, fibroblasts, and various stromal cells. Types of cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factor.
A secondary bile acid that is produced in order to aid in the digestion of fats and oils. It causes DNA damage and can cause tumorigenesis, particularly in the colon.
A drug that inhibits the enzyme pyruvate dehydrogenase kinase, thus increasing oxidative phosphorylation. Preliminary studies have shown DCA can slow the growth of certain tumors in animal and in vitro studies.
Presence in the blood of endotoxin, which, if derived from gram-negative rod-shaped bacteria may cause shock.
Genetic control by factors other than modification of the genetic code found in the sequence of DNA. Epigenetic changes determine which genes are being expressed, which in turn may influence disease risk. Some epigenetic changes are heritable.
The most common movement disorder involving a tremor of the arms, hangs or fingers particularly during voluntary movement such as eating or writing.
A protein that provides the instructions for genes responsible for the regulation of cellular replication, resistance to oxidative stress, metabolism, and DNA repair. FOXO3 may play an integral part in both longevity and tumor suppression. Variants of FOXO3 are associated with longevity in humans. Humans with a more active version of this gene have a 2.7-fold increased chance of living to be a centenarian.VIEW FOXO TOPIC
GABA (gamma aminobutyric acid)
A neurotransmitter produced in the brain that blocks impulses between nerve cells. GABA is the major inhibitory neurotransmitter in gray matter.
The process in which information stored in DNA is converted into instructions for making proteins or other molecules. Gene expression is highly regulated. It allows a cell to respond to factors in its environment and involves two processes: transcription and translation. Gene expression can be turned on or off, or it can simply be increased or decreased.
A hormone produced in the gut that signals hunger. Ghrelin acts on cells in the hypothalamus to stimulate appetite, increase food intake, and promote growth. Ghrelin’s effects are opposed by leptin, the “satiety hormone.” Sleep deprivation increases ghrelin levels and feelings of hunger, which can lead to weight gain and metabolic dysfunction.
Imatinib, marketed under the name "Gleevec," is an inhibitor of tyrosine-kinases and is successfully used in the treatment of multiple leukemias including Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
Glioblastoma Multiforme (GBM)
A fast-growing, aggressive cancer that develops from star-shaped glial cells (astrocytes and oligodendrocytes) within the brain.
A metabolic pathway in which the liver produces glucose from non-carbohydrate substrates including glycogenic amino acids (from protein) and glycerol (from lipids).
A survival mechanism the brain relies on during starvation. Glucose sparing occurs when the body utilizes fatty acids as its primary fuel and produces ketone bodies. The ketone bodies cross the blood-brain barrier and are used instead of glucose, thereby “sparing” glucose for use in other metabolic pathways, such as the pentose-phosphate pathway, which produces NADPH. NADPH is essential for the production of glutathione, one of the major antioxidants used in the body and brain.
Facilitates the transport of glucose across the cell membrane of skeletal muscles and adipose tissue cells, thereby removing glucose from the bloodstream.
An amino acid found in high concentration in every part of the body. In the nervous system, glutamate is by a wide margin the most abundant neurotransmitter in humans. It is used by every major excitatory information-transmitting pathway in the vertebrate brain, accounting in total for well over 90% of the synaptic connections in the human brain.
Glutamic Acid Decarboxylase
An enzyme that catalyzes the decarboxylation of glutamate into GABA, using vitamin B6 as a cofactor.
One of the most abundant non-essential amino acids in the human body. Glutamine plays key roles in several metabolic functions, including protein and glutathione synthesis, energy production, antioxidant status, and immune function. In addition, it regulates the expression of several genes. Although the body can typically produce all the glutamine it needs, during periods of metabolic stress it must rely on dietary sources of glutamine such as meats, fish, legumes, fruits, and vegetables.
An antioxidant compound produced by the body’s cells. Glutathione helps prevent damage from oxidative stress caused by the production of reactive oxygen species.
A sugar-alcohol compound that is the backbone of the triglycerides.
A series of enzyme-dependent reactions that breaks down glucose. Glycolysis converts glucose into pyruvate, releasing energy and producing ATP and NADH. In humans, glycolysis occurs in the cytosol and does not require oxygen.
Biological responses to low-dose exposures to toxins or other stressors such as exercise, heat, cold, fasting, and xenohormetics. Hormetic responses are generally favorable and elicit a wide array of protective mechanisms. Examples of xenohormetic substances include plant polyphenols – molecules that plants produce in response to stress. Some evidence suggests plant polyphenols may have longevity-conferring effects when consumed in the diet.
In a hyperbaric oxygen therapy chamber, the air pressure is increased to three times higher than normal air pressure. Under these conditions, your lungs can gather more oxygen than would be possible breathing 100% oxygen and normal air pressure.
Condition in which the body or a region of the body is deprived of adequate oxygen supply. Hypoxia may be classified as either generalized, affecting the whole body, or local, affecting a region of the body.
A critical element of the body’s immune response. Inflammation occurs when the body is exposed to harmful stimuli, such as pathogens, damaged cells, or irritants. It is a protective response that involves immune cells, cell-signaling proteins, and pro-inflammatory factors. Acute inflammation occurs after minor injuries or infections and is characterized by local redness, swelling, or fever. Chronic inflammation occurs on the cellular level in response to toxins or other stressors and is often “invisible.” It plays a key role in the development of many chronic diseases, including cancer, cardiovascular disease, and diabetes.
Insulin-like growth factor 1 (IGF-1)
One of the most potent natural activators of the AKT signaling pathway, stimulator of cell growth and proliferation, potent inhibitor of programmed cell death, primary mediator of the effects of growth hormone, and has been implicated in contributing to aging and enhancing the growth of cancer after it has been initiated. Similar in molecular structure to insulin, IGF-1 plays a role during childhood for growth and continues later in life to have anabolic, as well as neurotrophic effects. Protein intake increases IGF-1 levels in humans, independent of total caloric consumption.
A broad term that describes periods of voluntary abstention from food and (non-water) drinks, lasting several hours to days. Depending on the length of the fasting period and a variety of other factors, intermittent fasting may promote certain beneficial metabolic processes, such as the increased production of ketones due to the use of stored fat as an energy source. The phrase “intermittent fasting” may refer to any of the following:
- Time-restricted eating
- Alternate-day fasting
- Periodic fasting (multi-day)
Experiments that are performed using cells or microorganisms outside of their normal biological context and are often done in a test tube or petri dish.
A restriction in blood flow to tissues which causes a shortage of oxygen and glucose needed to keep tissue alive. Ischemia usually occurs when blood vessels become clogged and dysfunctional.
The end results of a physiological process in which your body has biochemically, physiologically, and metabolically shifted from using primarily glucose to using glucose and equal, or in some cases more, fatty acids and ketones for fuel. Being adapted represents an increase in production, utilization and metabolism, general oxidative capacity of cells, as well as actual ability to transport ketones.
Molecules (often simply called “ketones”) produced by the liver during the breakdown of fatty acids. Ketone production occurs during periods of low food intake (fasting), carbohydrate restrictive diets, starvation, or prolonged intense exercise. There are three types of ketone bodies: acetoacetate, beta-hydroxybutyrate, and acetone. Ketone bodies are readily used as energy by a diverse array of cell types, including neurons.
A weak base produced via the breakdown of glucose during exercise. Lactate can be "shuttled" to various tissues including muscle, heart, and brain, where it is used as an energy source. Evidence suggests that lactate is the preferred fuel of the brain. In clinical studies, lactate shows promise as a treatment for inflammatory conditions including traumatic brain injury and as a means to deliver fuel to working muscles.
Lactate Shuttle Theory
Lactate that is produced from an oxygen-independent metabolic pathway (glycolysis) is shuttled to various tissues including muscle, heart, and brain, where it is used as a substrate for oxygen-dependent energy production.
A medical condition characterized by the buildup of lactate in the body and can occur as the result of an underlying acute or chronic medical condition, medication or poisoning.
A medium chain fatty acid that is composed of 12 hydrocarbons that has very potent antiviral activity, particularly against viruses that contain a viral envelope. It also has antibacterial activity and it plays a role in appetite suppression. Coconut oil is a good source of lauric acid.
A measure of the number of small LDL particles in a person’s blood. LDL-P is thought to be a better predictor of heart attack risk than total LDL cholesterol. Apolipoprotein B (ApoB) is used as a marker for LDL-P since there is one ApoB molecule per LDL particle.
A hormone produced primarily by adipocytes (fat cells) that signals a feeling of satiety, or fullness, after a meal. Leptin acts on cells in the hypothalamus to reduce appetite and subsequent food intake. Leptin’s effects are opposed by ghrelin, the “hunger hormone.” Both acute and chronic sleep deprivation decrease leptin levels.
Large molecules consisting of a lipid and a polysaccharide with an O-antigen outer core. Lipopolysaccharides are found in the outer membrane of Gram-negative bacteria and elicit strong immune responses in animals. Also known as bacterial endotoxin.
The three basic components of the human diet. Macronutrients are consumed in large quantities and provide necessary energy for the body. They include carbohydrates, fats, and proteins.
Mechanistic target of rapamycin (mTOR)
A genetic pathway that senses amino acid concentrations and regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, autophagy, and transcription. It integrates other pathways including insulin, growth factors (such as IGF-1), and amino acids. mTOR plays a key role in mammalian metabolism and physiology, with important roles in the function of tissues including liver, muscle, white and brown adipose tissue, and the brain. It is dysregulated in many human diseases, such as diabetes, obesity, depression, and certain cancers. mTOR has two subunits, mTORC1 and mTORC2. Also referred to as “mammalian” target of rapamycin.
Rapamycin, the drug for which this pathway is named (and the anti-aging properties of which are subject to much study), was discovered in the 1970s and is used as an immunosuppressant in organ donor recipients.
Medium Chain Triglycerides (MCTs)
A type of triglyceride containing between 6-12 carbon atoms that is metabolized differently than triglycerides containing more than 12 carbons. Examples of MCTs include: caprylic acid (C8), capric acid (C10), and lauric acid (C12).
Cancer that has spread from the part of the body where it started to other parts of the body. When cancer cells break away from a tumor, they can travel to other areas of the body through the bloodstream or the lymph system.
A drug commonly used for the treatment of type 2 diabetes. Metformin is in a class of antihyperglycemic drugs called biguanides. It works by decreasing gluconeogenesis in the liver, reducing the amount of sugar absorbed in the gut, and increasing insulin sensitivity. A growing body of evidence suggests that metformin may prevent genomic instability by scavenging reactive oxygen species, increasing the activities of antioxidant enzymes, inhibiting macrophage recruitment and inflammatory responses, and stimulating DNA damage responses and DNA repair. 
 Najafi, Masoud, et al. "Metformin: Prevention of genomic instability and cancer: A review." Mutation Research/Genetic Toxicology and Environmental Mutagenesis 827 (2018): 1-8.
The collection of genomes of the microorganisms in a given niche. The human microbiome plays key roles in development, immunity, and nutrition. Dysfunction of the microbiome is associated with the pathology of several conditions, including obesity, depression, and autoimmune disorders such as type 1 diabetes, rheumatoid arthritis, muscular dystrophy, multiple sclerosis, and fibromyalgia.
Tiny organelles inside cells that produce energy in the presence of oxygen. Mitochondria are referred to as the "powerhouses of the cell" because of their role in the production of ATP (adenosine triphosphate). Mitochondria are continuously undergoing a process of self-renewal known as mitophagy in order to repair damage that occurs during their energy-generating activities.
The process by which new mitochondria are made inside cells. Many factors can activate mitochondrial biogenesis including exercise, cold shock, heat shock, fasting, and ketones. Mitochondrial biogenesis is regulated by the transcription factor peroxisome proliferator-activated receptor gamma coactivator 1-alpha, or PGC-1α.
The process by which damaged mitochondria are repaired by "fusing" together with normal mitochondria to exchange DNA and proteins and then once again "fissing" apart to give rise to two normal mitochondria.
Modified Atkins Diet
A change to the traditional "classic" ketogenic diet to make it less restrictive. One of the biggest differences is it doesn't have the same stringent restrictions on protein intake. It has been used to successfully treat drug-resistant epilepsy in adults.
A sulfur-containing amino acid. N-acetylcysteine promotes the body’s production of glutathione, an important antioxidant that helps reduce oxidative damage. It is commonly used for the treatment of acetaminophen overdose and chronic obstructive pulmonary disease. N-acetylcysteine modulates several neurological pathways, including glutamate dysregulation, oxidative stress, and inflammation. It may be useful as an adjunctive therapy for many psychiatric conditions, including PTSD and depression.
A protein typically present in the cytoplasm of mammalian cells. Nrf2 can relocate to the nucleus where it regulates the expression of hundreds of antioxidant and stress response proteins that protect against oxidative damage triggered by injury and inflammation. One of the most well-known naturally-occurring inducers of Nrf2 is sulforaphane, a compound derived from cruciferous vegetables such as broccoli.
A gene that has the potential to cause cancer. A proto-oncogene is a normal gene that regulates cell growth and proliferation but if it acquires a mutation that keeps it active all the time it can become an oncogene that allows cancer cells to survive when they otherwise would have died.
A type of movement disorder that causes fast low limb tremors resulting in unsteadiness while standing.
The process of generating energy that occurs when mitochondria couple oxygen with electrons that have been derived from different food sources including glucose, fatty acids, and amino acids.
A result of oxidative metabolism, which causes damage to DNA, lipids, proteins, mitochondria, and the cell. Oxidative stress occurs through the process of oxidative phosphorylation (the generation of energy) in mitochondria. It can also result from the generation of hypochlorite during immune activation.
Pentose phosphate pathway
An alternate pathway for the oxidation of glucose. The pentose phosphate pathway parallels glycolysis, but does not require or produce ATP; rather, it produces NADPH, which is necessary to create the cellular antioxidant glutathione. Like glycolysis, the pentose phosphate pathway occurs in the cytoplasm.
Polyunsaturated fats (PUFAs)
Dietary fats acids that have more than one unsaturated carbon bond in the molecule, such as omega-3 and omega-6 fatty acids. PUFAs are present in fish, nuts, and seeds and are more prone to oxidation than other fatty acids. PUFAs activate a master gene called PPAR, which is involved in lipid metabolism.
Positron Emission Tomography (PET) Scan
A type of imaging test that uses a radioactive substance (tracer) to look for disease in the body. For cancer detection/metastasis the tracer used is fluorodeoxyglucose, an analogue of glucose. The concentrations of tracer imaged indicate tissue metabolic activity as it corresponds to regional glucose uptake.
PPAR-alpha (Peroxisome proliferator-activated receptor alpha)
One of the three isotypes of a subfamily of nuclear receptor proteins (the PPARs) that functions as a transcription factor. PPAR-alpha is a major regulator of lipid metabolism in the liver and is activated under conditions of energy deprivation. It is necessary for the process of ketogenesis, a process that is a key adaptive response to prolonged fasting and is inducible by strict carbohydrate restriction. Activation of PPAR-alpha promotes uptake, utilization, and catabolism of fatty acids by upregulation of genes involved in fatty acid transport, fatty acid binding and activation, and peroxisomal and mitochondrial fatty acid β-oxidation. Expression of PPAR-alpha is highest in tissues that oxidize fatty acids at a rapid rate, especially the liver, but also brown adipose tissue (BAT), the heart, and kidney.
One of the enzymes involved in the process of converting pyruvate, which is derived from glucose, into energy in the form of ATP inside of the mitochondria.
Reactive Oxygen Species (ROS)
Oxygen-containing chemically-reactive molecules generated by oxidative phosphorylation and immune activation. ROS can damage cellular components, including lipids, proteins, mitochondria, and DNA. Examples of ROS include: peroxides, superoxide, hydroxyl radical, and singlet oxygen.
A related byproduct, reactive nitrogen species, is also produced naturally by the immune system. Examples of RNS include nitric oxide, peroxynitrite, and nitrogen dioxide.
The two species are often collectively referred to as ROS/RNS. Preventing and efficiently repairing damage from ROS (oxidative stress) and RNS (nitrosative stress) are among the key challenges our cells face in their fight against diseases of aging, including cancer.
Cellular respiration is the process by which oxygen is utilized to generate energy inside of the mitochondria.
The body's overwhelming and life-threatening response to an infection which can lead to tissue damage, organ failure, and death.
Short-Chain Fatty Acids
Also referred to as volatile fatty acids (VFAs) and possess an aliphatic tail of less than six carbon atoms. Produced when dietary fiber is fermented in the colon, and primarily absorbed through the portal vein during lipid digestion. The SCFA butyrate is particularly important for colon health because it is the primary energy source for colonic cells and has anti-carcinogenic as well as anti-inflammatory properties.
A molecule that allows cells to perceive and correctly respond to their microenvironment, which enables normal cellular function, tissue repair, immunity, cognition, and more. Hormones and neurotransmitters are examples of signaling molecules. There are many types of signaling molecules, however, including cAMP, nitric oxide, estrogen, norepinephrine, and even reactive oxygen species (ROS).
Single nucleotide polymorphism (SNP)
A change in one nucleotide DNA sequence in a gene that may or may not alter the function of the gene. SNPs, commonly called "snips," can affect phenotype such as hair and eye color, but they can also affect a person's disease risk, absorption and metabolism of nutrients, and much more. SNPs differ from mutations in terms of their frequency within a population: SNPs are detectable in >1 percent of the population, while mutations are detectable in <1 percent.
The Warburg effect
The observation that most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria as in most normal cells.
Type 2 diabetes
A metabolic disorder characterized by high blood sugar and insulin resistance. Type 2 diabetes is a progressive condition and is typically associated with overweight and low physical activity. Common symptoms include increased thirst, frequent urination, unexplained weight loss, increased hunger, fatigue, and impaired healing. Long-term complications from poorly controlled type 2 diabetes include heart disease, stroke, diabetic retinopathy (and subsequent blindness), kidney failure, and diminished peripheral blood flow which may lead to amputations.
A fat-soluble compound that is present inside the inner-mitochondrial membrane of cells. It plays a role in aerobic cellular respiration which produces energy in the presence of oxygen. The heart, liver, and kidney have the highest CoQ10 concentrations.
A progressive worsening of memory and other cognitive functions that is thought to be due to chronic reduced blood flow to the brain which is commonly due to the accumulation of cholesterol and other substances in the blood vessel walls that obstruct the flow of blood to the brain.
Vascular Endothelial Growth Factor (VEGF)
Originally known as vascular permeability factor (VPF). VEGF's normal function is to create new blood vessels during embryonic development, after injury, in muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. When VEGF is overexpressed, it can contribute to disease. Solid cancers cannot grow beyond a limited size without an adequate blood supply, and cancers that can express VEGF are able to grow and metastasize.
Very low-density LDL (VLDL)
A type of lipoprotein. VLDL enables fats and cholesterol to move within the water-based solution of the bloodstream. It is assembled in the liver from triglycerides, cholesterol, and apolipoproteins, and converted in the bloodstream to low-density lipoprotein (LDL). VLDL transports endogenous products (those made by the body), whereas chylomicrons transport exogenous products (those that come from the diet).
The maximum rate of oxygen consumption as measured during incremental exercise and indicates the aerobic fitness of an individual, and plays a role in endurance capacity during prolonged, submaximal exercise.
Sometimes called the protein immunoblot. Used to detect specific proteins in a sample of tissue homogenate or extract. It uses gel electrophoresis to separate native proteins by 3-D structure or denatured proteins by the length of the polypeptide. The proteins are then transferred to a membrane (typically nitrocellulose or PVDF), where they are stained with antibodies specific to the target protein.
Member support keeps us strong.
If you enjoy the fruits of , you can participate in helping us to keep improving it. Creating a pay-what-you-can subscription does just that! Plus, we throw in occasional member perks and, more importantly, churn out the best possible content without concerning ourselves with the wishes of any dark overlords.
Our website is 100% supported by people like you through this pay-what-you-can mechanism.
Fundamentals$5 / month
Loyal Fan$10 / month
Super Fan$25 / month
Power Supporter$50 / month
Heroic Supporter$125 / month